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ABSTRACT OF THE DISSERTATION 
THE ROLE OF REDOX SIGNALING IN THE MOLECULAR MECHANISM OF 
TAMOXIFEN RESISTANCE IN BREAST CANCER. 
by 
Nana Aisha Garba 
Florida International University, 2011 
Miami, Florida 
Professor Deodutta Roy, Major Professor 
The emergence of tamoxifen or aromatase inhibitor resistance is a major problem in the 
treatment of breast cancer. The molecular signaling mechanism of antiestrogen resistance 
is not clear. Understanding the mechanisms by which resistance to these agents arise 
could have major clinical implications for preventing or circumventing it. Therefore, in 
this dissertation we have investigated the molecular mechanisms underlying antiestrogen 
resistance by studying the contributions of reactive oxygen species (ROS)-induced redox 
signaling pathways in antiestrogen resistant breast cancer cells. Our hypothesis is that the 
conversion of breast tumors to a tamoxifen-resistant phenotype is associated with a 
progressive shift towards a pro-oxidant environment of cells as a result of oxidative 
stress. The hypothesis of this dissertation  was tested in an in vitro 2-D cell culture model 
employing state of the art biochemical and molecular techniques, including gene 
overexpression, immunoprecipitation, Western blotting, confocal imaging, ChIP, Real-
Time RT-PCR, and anchorage-independent cell growth assays.  We observed that 
tamoxifen (TAM) acts like both an oxidant and an antioxidant. Exposure of tamoxifen 
resistant LCC2 cell to TAM or 17 beta-estradiol (E2) induced the formation of reactive 
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oxidant species (ROS). The formation of E2-induced ROS was inhibited by co-treatment 
with TAM, similar to cells pretreated with antioxidants. In LCC2 cells, treatments with 
either E2 or TAM were capable of inducing cell proliferation which was then inhibited by 
biological and chemical antioxidants. Exposure of LCC2 cells to tamoxifen resulted in a 
decrease in p27 expression. The LCC2 cells exposed to TAM showed an increase in p27 
phosphorylation on T157 and T187. Conversely, antioxidant treatment showed an 
increase in p27 expression and a decrease in p27 phosphorylation on T157 and T187 in 
TAM exposed cells which were similar to the effects of Fulvestrant. In line with previous 
studies, we showed an increase in the binding of cyclin E–Cdk2 and in the level of p27 in 
TAM exposed cells that overexpressed biological antioxidants. Together these findings 
highly suggest that lowering the oxidant state of antiestrogen resistant LCC2 cells, 
increases LCC2 susceptibility to tamoxifen via the cyclin dependent kinase inhibitor p27. 
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I. INTRODUCTION 
The fact that a majority of breast cancer express estrogen receptor alpha (ERα), has 
informed the use of antiestrogens as one of the drugs of choice for ER+ breast cancers. 
Anti-estrogens which act by inhibiting the function of ERs include tamoxifen, raloxifen 
and fulvestrant1. Tamoxifen is the most commonly used treatment for patients with ER+ 
breast cancer and its use as a breast cancer preventative agent and an adjuvant therapy in 
early cancer has been shown to improve the overall survival2, 3. Furthermore, the 
extensive use of tamoxifen has made a significant contribution to the reduction in breast 
cancer mortality seen over the last two decades.  
 
However, in spite of the obvious benefits of tamoxifen in breast cancer treatment, almost 
all patients with metastatic breast disease and as many as 40% of patients receiving 
adjuvant tamoxifen eventually develop resistance and die from their disease1. Hence the 
issue of tamoxifen resistance has been a major setback in an otherwise successful 
treatment of ER+ breast cancer.  
  
Though a number of pathways have been proposed and explored, to date there has been 
no clear mechanism implicated in the development of anti-estrogen resistance. A hitherto 
unexplored mechanism involves the role of reactive oxygen species (ROS) in the 
mechanism of tamoxifen resistance. (ROS) comprise of either partially reduced 
metabolites of oxygen such as superoxide anions (O2− •); peroxyl radicals (LOO.) and 
hydroxyl radicals (OH·) or non-radical molecules  like hydrogen peroxide (H2O2)  and  
singlet oxygen (1O2); which have a higher reactivity than molecular oxygen4.  They are 
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products of cellular metabolism which have been shown to induce oxidative stress. An 
excessive and/or sustained increase in ROS production has been implicated in the 
pathogenesis of cancer5, 6. Furthermore, ROS induced oxidative stress has been shown to 
initiate a number of different responses including cell proliferation and transformation; 
alteration of intracellular redox state and the oxidative modification of certain signaling 
proteins resulting in the post translational modification7 of their downstream targets. 
Interestingly, like estrogen, tamoxifen has been shown to induce ROS formation, making 
it probable that tamoxifen induced ROS generated as a result of prolong tamoxifen 
treatment of breast cancer patients may play a vital role in the development of tamoxifen 
resistance.  
 
As protection against oxidative stress, cells have several enzymic and nonenzymic 
antioxidants or reductants that maintain the intracellular redox environment in a 
principally reduced state. Typically the enzyme superoxide dismutase (SOD) catalyses 
the conversion of O2− to H2O2, and then the H2O2 generated is degraded to H2O by 
several cellular enzymes, usually Catalase or glutathione peroxidase coupled with 
glutathione reductase8, 9. It is however interesting to note that in most cancer  tissue  the 
levels/ activity of manganese superoxide dismutase and  Catalase have been found to be 
almost always low. Making a case for the existance of a  pro-oxidative environment in 
cancer cells that may result in an oxidative stress surge and redox signaling culminating 
in uninhibited cell proliferation.  
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Hypothesis and Specific Aims  
We hypothesize that the conversion of breast tumors to a tamoxifen-resistant phenotype 
is associated with a progressive shift towards a pro-oxidant environment, as a result of 
chronic oxidative stress. We further postulate that an increase in reactive oxygen species 
(ROS) levels promotes either the loss of p27 inhibitory function or NRF-1 activation 
through the inactivation of protein tyrosine phosphates (PTPs) with consequent changes 
in p27 and/or NRF-1 phosphorylation.  
     
To test this hypothesis, we explored the following Specific Aims: 
Aim 1. To investigate whether anti-estrogens prevent estrogen-mediated progression of 
cell cycle by counteracting estrogen-induced ROS signaling. To further investigate if 
reducing the oxidative environment of anti-estrogen-resistant breast cancer cells restores 
the anti-proliferative action of tamoxifen.  
 
Aim 2. To determine mechanisms by which a pro-oxidative state may promote p27 
inactivation, and thus cell cycle progression. 
  
Aim 3. To determine mechanisms whereby a pro-oxidative state may promote oxidation 
of protein tyrosine phosphatase PTEN, NRF-1 activation and cell cycle progression. 
 
Findings of this study will elucidate the roles of the cellular redox state, redox signaling 
pathways, PTPs and p27 in anti-estrogen resistance, and may lead to new therapeutic 
strategies to delay or even prevent this important clinical problem. This is a new line of 
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research that may lay the groundwork for clinical trials of anti-estrogens plus antioxidant-
based drugs for the prevention and treatment of estrogen-dependent breast cancer.  
 
II. LITERATURE REVIEW: 
THE ROLE OF REDOX SIGNALING IN THE MOLECULAR MECHANISM OF 
TAMOXIFEN REISTANCE IN BREAST CANCER TREATMENT 
 
Abstract 
Anti-estrogens are one of the classes of drugs used to treat ER+ breast cancer. Since their 
discovery they have been the drugs of choice in breast cancer treatment; prevention and 
adjuvant therapy for early breast cancer cases. Although anti-estrogens have been 
beneficial to a large number of patients, unfortunately about 40% of breast cancer 
patients and a majority of patients with metastatic breast disease who were initially 
responsive to the drugs will relapse and die of the disease. In spite of the current break-
through in our knowledge of the molecular mechanisms that contribute to resistance, anti-
estrogen resistance remains a major setback in the treatment of ER+ breast cancer. In this 
review we examine the previously unexplored role of reactive oxygen species (ROS) and 
redox signaling in the molecular mechanism that contribute to breast cancer resistance to 
anti-estrogens. 
 
Introduction 
In the majority of invasive breast tumors estrogen receptor alpha (ERα) is often up-
regulated while ERβ is down-regulated. This finding is the basis for the therapeutic use of 
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antiestrogens, which are drugs that disrupt the actions of estrogen and ERα1. The types of 
antiestrogens used include those that inhibit the function of estrogen receptors such as 
tamoxifen, raloxifene, and ICI 182,780 (fulvestrant), or the aromatase inhibitors such as 
letrozole and exemestane which block the conversion of androgens into biologically 
active estrogens.Over the years the successful use of these groups of drugs has been 
plagued by the emergence of drug resistance, which to date remains a major problem in 
the treatment of breast cancer. 
 
Herein, we reviewed the role of estrogen and its receptors in the development of breast 
cancer and the function of tamoxifen as an antiestrogen. We also examined the role of 
reactive oxygen species (ROS) as signaling molecules and how they may induce 
antiestrogen resistance by altering the post-translational status of certain signaling 
proteins which are key players in the cell cycle.  
 
 An overview of Estrogen and ER action 
The human breast like that of other mammalian species contains both epithelial and 
mesenchymal components and a vast majority of  malignant tumors are epithelial in 
origin1.  
 
In normal breast cells, estrogen and estrogen receptors are critical regulators which 
enable the mammary epithelial cells to undergo proliferation, differentiation, apoptosis 
and remodeling in the course of the mammalian reproductive lifespan1, 10, 11.  
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Studies have shown that estrogens initiate different growth responses in tissues 
depending on the cell type, the dose and the timing of exposure 12. Moreover, it is now 
generally accepted that, in addition to its role in the promotion of breast tumors, estrogen 
also supports the growth of pre-neoplastic and malignant cells through ER-mediated 
signaling pathways13.  
 
The conventional model of estrogen action is based on its binding to ERα/β receptors, 
which initiates transcription either directly by binding to estrogen response elements 
(EREs) in the promoter region of target genes or indirectly through the phosphorylation 
of signaling proteins involved in cell cycle progression 14, 15. Overall, estrogen regulates 
the expression of many genes important for normal cell physiology and growth of some 
breast tumors 16. 
 
Both experimental and epidemiologic data suggest that estrogen plays a significant role in 
carcinogenesis17 , 15. In malignant breast tissue, the action of estrogen and its steroid 
receptors is dysregulated, resulting in a shift to proliferation without differentiation and 
apoptosis, and an increase in the percentage of epithelial cells expressing ERα. 
Additionally, cell proliferation makes a change from paracrine to autocrine growth 18 . It 
is noteworthy that the risk of breast cancer is, in part, due to the duration of proliferation 
without differentiation.  
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Estrogen Receptors (ER) 
Normal human breast cells contain two types of E2 receptors, namely ERα and ERβ, 
which are the products of separate genes. ERα is expressed in 15 – 30% of the luminal 
epithelial cells (so called estrogen receptor positive cells) while ERβ is more widely 
expressed in the mammary tissue1;19, 20. ERβ is co-expressed with ERα in the luminal 
epithelial cells, but can also be found in the myoepithelial cells as well as in the stromal 
cells. In the normal luminal epithelial breast cells, estrogen-dependent proliferation 
occurs in a paracrine manner with ERα containing cells producing growth factors that 
induce proliferation in adjacent estrogen-negative cells. 
 
Deletion of both ERα and ERβ genes has revealed the significance of E2 for normal 
female sex organ development and function 20;21. Both in vivo and in vitro studies in 
mammals have postulated that E2 plays a considerable role in the maintenance of bone22 , 
vascular integrity, and brain function. Estrogen has also been shown to be a significant 
growth and survival factor for human breast cancer cells 23, 24. ERs act principally as 
nuclear transcription factors, an event that is enhanced by ligand binding. Though a 
separate pool of receptors for E2 in the cytoplasm and plasma membrane have been 
identified, the mechanisms of action and cellular functions of these proteins are just 
beginning to be unraveled.  
 
Estrogen Receptors: Nuclear/genomic pathway 
The ‘genomic action’ of E2 occurs after a time-lag of at least 2 h following E2 
stimulation. This action accounts for some hormone functions in physiological and 
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pathological situations 25, 26.The nuclear ER contains domains lettered A through F, with 
activation function (AF)-1 (ligand independent) and AF-2 (ligand dependent) facilitating 
the transactivation of target genes27. 
 
In the so called ligand dependent pathway, ER functions in the nucleus as a 
transcriptional regulator of specific genes. The receptor protein has a ligand-binding 
domain (AF-2), several transcription activation domains, and a DNA-binding domain that 
interacts with specific regions in the promoter of target genes, including sites known as 
estrogen-responsive elements (ERE) 28-30. The binding of estrogen to ER induces 
phosphorylation of the receptor, alters its conformation, and triggers receptor 
dimerization. 
 
The ER protein in the nucleus can also modify transcription of genes through protein-
protein interactions. In this way, ER can function much like a coactivator protein itself by 
binding to other transcription factors and recruiting acetyltransferases to complexes 
bound to activator protein or SP-1 sites on DNA31. This is how estrogen helps to regulate 
genes encoding proteins such as cyclin D1, insulin-like growth factor I receptor (IGF-IR), 
and collagenase. ER has also been to be able to decrease the expression of many genes32. 
 
In the ligand-independent pathway, the estrogen receptor translocates to the nuclear 
membrane from the cytosol and can activate transcription in a ligand-independent 
fashion33. These transcriptional activities of ER have been called its classical or genomic 
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activity. From a functional perspective, a more appropriate term is nuclear-initiated 
steroid signaling. 
 
Membrane-initiated Estrogen signaling 
In contrast to the nuclear effects, ER functions that can occur very rapidly in the cell 
before new gene transcription takes place have been identified. This membrane-initiated 
steroid signaling could occur outside the nucleus or even in the cell membrane 34. A 
number of studies based on endothelial and breast cancer cells have been able to show 
that a small group of ER is positioned outside the nucleus in the cytoplasm or bound to 
the plasma membrane35, 36 37, 38. It is thought that the presence of a membrane-bound ER 
may explain the previously identified short-term effects of estrogen (occurring within 
minutes) in cultured cells39, 40. Further investigations have indicated that E2 rapidly 
activates signaling, such as calcium flux,41 phospholipase C activation 42 and inositol 
trisphosphate (IP3) generation. Most studies suggest that these actions necessitates E2 
binding to ERs. In neural cells, ERs can activate protein kinase C and protein kinase A. 
They can also uncouple opioidergic and gabanergic receptors from their effector 
signaling molecules40. These signaling events are likely to be as a result of E2 activation 
of G proteins. Therefore, ERs appear to be part of the large family of G-protein-coupled 
receptors (GPCR). After several G proteins are activated, E2-ER can then trigger 
signaling cascades that terminate in a cell biological function. 
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Antiestrogen (Tamoxifen) Action 
Tamoxifen belongs to a class of therapeutic agents called the selective estrogen receptor 
modulators (SERMs). These drug function as estrogen receptor (ER) antagonists in breast 
tissue and  as ER agonists in the endometrium, heart and bones43. 4-hydroxy-tamoxifen is 
an active metabolite of tamoxifen, which has been shown to compete for binding with 
natural estrogen to the ERα with high affinity44, 45. 
 
Subsequent to the antagonist binding to ERα, a different 3-dimensional structure is 
elicited in the receptor, which renders it unable to enhance specific gene expression. 
Therefore antiestrogens interrupt the estrogen-induced signals, which can result in the 
inhibition of cell proliferation, tumor growth arrest, and induction of apoptosis46; 47, 48. 
 
In vitro tamoxifen has been shown to induce G1 phase cell cycle arrest in ER-positive 
breast cancer cells exposed to estrogens. 1; 49, 50;51 creating an avenue by which genes that 
control cell cycle progression could significantly impact drug sensitivity and resistance. 
Furthermore, tamoxifen has the capacity to indirectly decrease levels of cyclin D152 .  
 
In vivo, tamoxifen inhibits estrogen-stimulated growth of MCF7 xenografts in mice and 
prevents development of breast cancer in the NMU and DMBA rodent models53, 54. 
Similar to estrogens, tamoxifen increases the expression of IGF-I and vascular 
endothelial cell growth factor in the uterus.55, 56 In clinical specimens acquired 
sequentially from patients with breast cancer, administration of tamoxifen has been 
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shown to reduce proliferation, upregulate ER expression, downregulate TGFα and induce 
stromal TGFβ157-60.  
 
Other classes of therapeutic agents are the selective estrogen receptor down regulators 
(SERDs) and aromatase inhibitors (AI). SERDs include ICI182780 (Fulvestrant), which 
is a pure estrogen antagonist with a 100-fold greater affinity for ER than tamoxifen. By 
binding ER it inhibits receptor dimerization and abrogates estrogen signaling17. 
Aromatase inhibitors are a second line therapy for post–menopausal patients who have 
progressed after tamoxifen treatment. They act by inhibiting the action of aromatase 
which is an enzyme necessary for the conversion of androgens to estrogens. 
It is interesting to note that the majority of tumors that develop resistance over time 
continue to express ERα10;11 . Furthermore, many of the tamoxifen-resistant tumors still 
respond to fulvestrant and AIs, indicating that estrogen remains an important regulator of 
tumor growth under these circumstances10. These data provide support for the idea that 
endocrine targeted therapies can lead to the activation of novel signaling pathways that 
evade the effects of antiestrogens.  
 
Redox signaling 
Redox Signaling is process whereby activated or free radicals and reactive oxygen 
species act as messengers in the biological system. It involves a vital and continuous 
process by which human cells communicate with each other and carry out essential 
functions in the body. Redox signaling often entails oxidation-reduction specific 
reactions. 
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Unlike signal transduction which usually involves both reversible and irreversible 
modifications of second messengers and proteins, redox signaling entails at least one 
reversible reaction involving the oxidation of a signaling molecule by a reactive species. 
It may therefore be inferred that the reaction of reactive oxygen or nitrogen species with 
their target is akin to the on-off signaling associated with phosphorylation than it is to the 
nonenzymatic lipid peroxidation.  
 
According to Forman et al., 61 redox signaling occurs when at least one step in a signaling 
pathway involves one of its components being specifically modified by a reactive species 
through a reaction that is chemically reversible under physiological conditionsand/or 
enzymatically catalyzed. 
 
Signaling molecules: Reactive Oxygen or Nitrogen species 
Both reactive oxygen and nitrogen species are known redox signaling molecules. 
Reactive nitrogen species (RNS) are molecules having nitrogen atoms, which because of 
their chemistry, are regarded as being highly reactive towards other cellular components. 
These molecules may or may not have unpaired electrons. Examples of RNS include 
radicals like Nitric Oxide (NO.), Nitrogen dioxide (NO2.) and non rasicals like 
Peroxynitrite (ONOO-). On the other hand, Reactive oxygen species (ROS) constitutes 
either partially reduced metabolites of oxygen such as superoxide anions (O2− •); peroxyl 
radicals (LOO.) and hydroxyl radicals (OH·) or non-radical molecules  like hydrogen 
peroxide (H2O2)  and  singlet oxygen (1O2); which have a higher reactivity than molecular 
 13 
oxygen. ROS are by-products of normal cellular aerobic metabolism and the exposure of 
cells to certain forms of stress results in an increase in the level of ROS generated. It is 
note worthy that high level of reactive oxygen species are injurious to cells because of 
their tendency to react with a number of intracellular targets, such as proteins, lipids, and 
DNA. Conversely, quite a number of studies have shown that reactive oxygen species 
posses a variety of physiologic functions at low concentrations. These functions include 
but are not limited to: the  regulation  of  gene transcription 62, signal  transduction 
pathways 63-66 mitosis 67,  apoptosis 67, 68, and senescence 68, 69. Additionally, it has been 
shown that the stimulated production of oxidants plays a vital role in the mitogenic 
response to many growth factors 63, 66, 70 For example, ROS  have been shown to play a 
vital role in cell growth mediated by 17β-estradiol (E2),71 peptide growth factors and 
cytokines including PDGF 66, vascular endothelial growth factor, insulin, and tumor 
necrosis factor72.  
 
Regarding their role as signaling molecules, some reactive oxygen species such as H2O2 , 
are considered key signaling molecules, while others appear to be particularly harmful to 
living systems73. In higher organisms, low to moderate concentrations of NO and ROS 
are utilized as signaling molecules for other normal cellular  functions like: their 
physiological roles in the cellular responses to oxygenation, as in the defense against 
infectious agents; the initiation of a number of cellular signaling systems and the 
induction of a mitogenic response 72, 74, 75. Furthermore, exposure to a variety of non-
physiologically significant concentrations of ROS or RNS that induce oxidative stress but 
do not kill cells can stimulate responses such as repair, adaptation, or transformation76. 
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On the other hand, excessive and/or sustained increase in ROS production has been 
implicated in the pathogenesis of cancer 5, 5, 6.  as well as other metabolic diseases like 
diabetes mellitus72. Tumor cells have been shown to have a high and persistent oxidative 
stress 77. Free radicals are involved in initiation 78 as well as promotion/ progression 
stages of tumorigenesis 79, 80 while inhibitors and scavengers of ROS inhibit these stages 
of tumor development 81, 82.  
 
Based on work done on the release of ROS by non phagocytic cells, and on cells where 
ROS have no apparent role, ROS has been shown to be key signaling molecules, even 
though their exact mode of action was relatively unknown. Currently several studies have 
shown the ability of ROS to induce necrosis at high concentrations, as well as its role in 
the induction/inhibition of cell proliferation, and in the activation/inhibition of 
apoptosis83, 84.  
 
Sources of reactive oxygen species 
ROS (usually O2− •) can be generated intracellularly by a number of enzymes including 
NADPH oxidase which upon stimulation undergo a respiratory burst, with the release of 
superoxide into the phagosome85, 86 the endoplasmic reticulum which is another site of 
electron transport, where O2− • is generated by the leakage of electrons from NADPH 
cytochrome P450 reductase87 cytosolic oxidases; xanthine oxidase and lipoxygenase, and 
the mitochondrion. In the mitochondria, reactive oxygen species like O2− • and H2O2 are 
often generated as by-products of electron transfer reactions that occur during the 
operation of the mitochondrial electron transport chain. ROS is generated in the 
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mitochondrial electron transport chain as a result of “leakage”88 of electrons from 
electron carriers that are passed directly to oxygen, reducing it to O2 −. An evidence of 
this mode of ROS generation is substantiated by the fact that the mitochondria contain 
their own superoxide dismutase, an inducible Mn2+-dependent enzyme 89, for rapid 
elimination of such reactive species and from a study by Felty et al.90 which identified the 
mitochondrion as a major source of estrogen-induced ROS in breast cancer cells. 
 
ROS is also generated by the metabolism of arachidonic acid by the enzymes 
cyclooxygenases and lipoxygenases. Prostaglandin H synthase is a major enzyme in the 
biosynthesis of prostaglandins, prostacyclins, and thromboxanes. Prostaglandin H 
synthase possesses both cyclooxygenase and hydroperoxidase activity91, hence it has the 
capacity to generate ROS as oxidizing equivalents via side-chain reactions that are 
dependent upon the presence of a suitable reducing substrate such as NADH or NADPH . 
 
Nitric oxide (NO  ) is generated from the conversion of the amino acid l-arginine to l-
citrulline by NOS. NO  is an important reactive species containing both nitrogen and 
oxygen. Production of NO  by neutrophils is well documented, but there are important 
interspecies differences in the amount of NO  produced: rodent neutrophils produce 
substantially more ROS than human cells 92;93. 
 
17β-estradiol (Estrogen) induces ROS formation 
Presently there are several postulates that E2-induced mitochondrial ROS is involved in 
the growth and proliferation of estrogen-dependent cells. Felty et al.94 reported that 
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physiological concentrations of E2 stimulate a rapid generation of intracellular ROS and 
intracellular ROS have been implicated in the promotion of rapid cell cycle activity in 
neoplastic cells. 
 
One attribute of rapidly dividing cancer cells is their ability to generate significant 
quantities of intracellular ROS. Studies have shown that estrogen-induced stimulation of 
both MCF-7 and macrophage cells is partly due to the effect of ROS95, 96. In an 
unpublished data by Singh et al., it was observed that scavengers of ROS such as N-
acetylcysteine, ebselen, and catalase inhibited the estrogen-induced growth of MCF-7 
cells, lending credence to the proposed role of ROS as an autocrine growth signal in 
estrogen-induced cell proliferation97. Based on a study by Taylor et al.98, which 
established that oxidative stress modifies mitochondrial matrix protein thiols, Felty and 
Roy 97 extrapolated that an estrogen-mediated cell growth through mitochondrial-
generated ROS signaling molecules may exist. This was based on the reasoning that since 
exposure to estrogen can generate mitochondrial ROS, the oxidation of thiols in response 
to estrogen converts the oxidative stress to a change in protein function that is involved in 
cell growth.  
 
In a study of E2-induced ROS generation in MCF-7 and other cells, the measurable 
events occurred earlier than a regular ER-mediated genomic action. This lead to the belief 
that E2-stimulated ROS production does not depend solely on the presence of the ER in 
breast cancer cells. Further more, because the ER-negative cell line MDA-MB 468 upon 
E2 stimulation was able to produce ROS equal in amount to that of ER-positive cell lines 
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such as MCF7, T47D, and ZR75, it was inferred that, ROS formation upon E2 exposure 
might explain oxidative damage to hormone-dependent tumors and ensuing genetic 
alterations 99, 100. A few studies have also revealed that E2-induced production of ROS 
also provides systematic support for the generation of mutations by physiological 
concentrations of estrogens101, 102. 
 
In 2006, Felty103 showed that estrogen exposure of human umblical vein and endothelial 
cells (HUVECs) stimulated a rapid production of intracellular ROS that is involved in 
signaling endothelial cell growth. He also showed that the early E2 signaling did not 
require ER-mediated genomic signaling, because E2-induced growth could be inhibited 
by antioxidants. The functional outcomes of E2-induced ROS formation include an 
increase in phosphorylation of the signaling proteins C-jun and CREB, as well as the 
activation of the binding of three oxidant-sensitive transcription factors AP-1, CREB, and  
possibly nuclear respiratory factor 1(NRF-1)90. 
 
Additional findings by Felty et al. suggest that E2-induced mitochondrial ROS modulate 
G1 to S transition and some of the early G1 genes through a nongenomic, ER-
independent signaling pathway resulting in the conclusion that estrogen-induced 
mitochondrial oxidants control the early stage of cell cycle progression, which could 
provides the basis for the discovery of novel antioxidant-based drugs or antioxidant gene 
therapies for the prevention and treatment of estrogen-dependent breast cancer 104. 
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Tamoxifen induces ROS formation  
In addition to its role in inhibiting the growth of ER-positive breast cancer cells through 
its antiestrogenic properties 105, tamoxifen also appears to have effects on many ER-
negative cancer cells106-109. Though the mechanism of this action is not known, as in the 
case of E2, studies have found the effect of tamoxifen on ER-negative cells to be related 
to its non-genomic actions.  
 
It has been reported that tamoxifen-induced apoptosis in ER-negative HepG2 human 
hepatoma cells is mediated by increased intracellular Ca2+ 110 and a consequent 
generation of ROS 111. In the study by Lee et al.111, ROS appeared to be a downstream 
signal of elevated intracellular Ca2+ , given that their generation was temporally preceded 
by elevation of intracellular Ca2+  within a time frame, and completely inhibited by 
intracellular and extracellular Ca2+ chelating agents. Another study by Kallio et al 112 
showed that at high doses tamoxifen was able to induce apoptosis through the production 
of ROS in MCF 7 cells. 
 
Tamoxifen-induced ROS generation has been shown to be produced by membrane bound 
NADPH oxidase113 and not to the activation of enzymes like microsomal enzyme, 
cytochrome P-450, and numerous catalytic cytosolic enzymes, including cyclooxygenase. 
The is because ROS production was not altered by treatment with specific inhibitors of 
these enzymes111. NADPH oxidase has also been functionally active in nonphagocytic 
cells, including endothelial cells114, vascular smooth muscle cells,115 neuroepithelial 
bodies of the lung 116 and type I cells of the carotid body117. The components of the 
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NADPH oxidase have been expressed in HepG2 cells118, 119 and the enzyme appears to be 
a major source of ROS produced by hypoxia118.  Lee et al 111. also reported that the 
NADPH oxidase acts as a major site of the tamoxifen-induced ROS production.  
 
Tamoxifen as a scavenger of ROS 
Several studies including a study by Kuo et al 120 have shown that 4-OHT (an active 
metabolite of Tamoxifen) possesses a potent superoxide anion radical-scavenging 
tendency. The presence of phenolic groups in tamoxifen, (much like raloxifen and E2) 
confers its antioxidant action chiefly because phenolic structures have the capacity to 
bind iron, in addition to reducing peroxyl or alkoxyl radicals 121. In addition, several 
studies 239;122, 123;124;125 including one by Arteaga et al.126, 127 have shown that tamoxifen is 
a scavenger of ROS. 
 
The role of ROS in oxidative stress and redox signaling 
The harmful effect of free reactive oxygen and/or nitrogen species resulting in possible 
biological damage is called oxidative stress and nitrosative stress respectively128-130. 
Oxidative and nitrosative stress occur in biological systems following an over production 
of ROS/RNS as well as an accompanying insufficiency of enzymatic and non-enzymatic 
antioxidants. Simply put, oxidative stress refers to a disturbance in the balance between 
pro-oxidant/antioxidant reactions in living organisms. As mentioned previously in this 
review, excess ROS can damage cellular lipids, proteins, or DNA by hindering their 
natural function. Hence it comes as no surprise that oxidative stress has been implicated 
in a number of human diseases as well as in the ageing process131.  
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Redox regulation, on the other hand, is a very important system responsible for the fairly 
fragile balance between the beneficial and the harmful effects of ROS/RNS. According to 
Droge 72, the redox regulation process protects living organisms from a variety of 
oxidative stresses and maintains the so-called “redox homeostasis” by controlling the 
redox status in the living system132. 
 
Redox balance, which is the ratio between oxidizing and reducing species within the cell, 
plays a significant role in the regulation of signaling pathways, including kinase and 
phosphatase activity as well as gene expression through regulation of the function of 
transcription factors 7, 133, 134, 134 
 
As protection against oxidative radical stress, cells have several enzymic and nonenzymic 
anti-oxidants or reductants that maintain the intracellular redox environment in an 
especially reduced state. Typically the enzyme superoxide dismutase (SOD) catalyses the 
conversion of O2− to H2O2, and then the H2O2 generated is degraded to H2O by several 
cellular enzymes, usually catalase or glutathione peroxidase coupled with glutathione 
reductase 135, 136 (see eqn 1).  
O2 + e− → O2-•        SOD          H2O2    Catalase           H2O (eqn1)  
                                                  GSH peroxidase              
 
 
Other relevant scavengers include thioredoxin coupled with thioredoxin reductase, and 
glutaredoxin, which uses GSH as a substrate. GSH plays a central role in maintaining 
redox homeostasis.The GSH to oxidized glutathione ratio (2GSH/GSSG) provides an 
estimate of cellular redox buffering ability137. Forman et al.138 have argued that in 
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contrast to oxidative stress which is induced as a response to damaged molecules, redox 
signaling always involves responses that are specific to oxidation reduction reactions. 
  
Oxidative stress often initiates a number of varied responses ranging from cell 
proliferation and transformation to apoptosis and senescence. The type of effect induced 
depends on the types and amounts of ROS and reactive nitrogen species (RNS) that are 
generated, the duration of the oxidative burst, the cellular antioxidant defense systems, 
and the cellular context in which oxidative stress occurs. For example, low concentration 
exposure of cells to hydrogen peroxide (H2O2) have been shown to mediate platelet-
derived growth factor (PDGF)-induced vascular smooth muscle proliferation 139, whereas 
moderate concentrations of H2O2 induce growth arrest while high concentrations induce 
apoptosis and/or necrosis140. Enzymes that are involved in oxidant generation or oxidant 
scavenging are also critically involved in the regulation of cell growth141-144. It has also 
been documented in several biochemical studies that, in most cancer  tissue  the levels/ 
activity of manganese superoxide dismutase and  catalase are almost always low while 
that of  copper, zinc superoxide dismutase is usually low. Conversely, the activity of 
glutathione peroxidase in  tumor  tissue is variable if measured with biochemical methods 
using tissue  homogenates145-148.These findings show an association between low 
antioxidant levels vis a viz oxidative stress and cancer.  
 
Chemistry of ROS 
Presently, there are two main models of ROS signaling namely: (i) alteration of 
intracellular redox state and (ii) oxidative modification of proteins7. In the alteration of 
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intracellular redox state, the cytosol is usually maintained in strong reducing conditions 
often achieved by the redox balancing action of intracellular thiols like glutathione (GSH) 
and thioredoxin (TRX).  
 
Studies have shown that depending on their local environment, thiolates (S-) react with 
H2O2 a lot faster than thiols (SH)149. It has also been established that in the active sites of 
proteins like TRX and Prx one cysteine exists in the thiolate form making it more 
amenable to reacting with H2O2. In the following redox reactions involving H2O2 and a 
thiolate (RS-)61 (see fig. 1A), the sulfenate (RSO-) that is formed then reacts with a thiol 
to form a disulphide bond (see fig.1B). Then the original thiolate is restored by exchange 
with another thiolate (see fig 1C). 
 
Oxidative modification of proteins 
ROS can change the structure and function of proteins by modifying certain critical 
amino acid residues, thereby inducing protein dimerization, and interaction with Fe-S 
moieties or other metal complexes7. The most recognized oxidative modifications of 
critical amino acids within the functional domain of proteins involve cysteine residues. 
The sulfhydryl group (-SH) of a single cysteine residue may be oxidized to form sulfenic 
(-SOH), sulfinic (-SO2H), sulfonic (-SO3H), or S-glutathionylated (-SSG) derivatives7, 150. 
When the critical cysteine is located within its catalytic domain, an alteration of this 
nature could vary the enzyme activity151. On the other hand, when the critical protein is 
within the DNA-binding motif of a transcription factor, the ability of the transcription 
factor to bind DNA is affected152. For example, the active site of all but one of the protein 
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peroxiredoxin (Prx) contains cysteines out of which one is a thiolate (S-). Prx will react 
with ROS to form sulfenic acid (see fig. 2A). A second thiol then reacts with the 
sulfenate to form an intramolecular disulphide (see fig 2B). In the third and final step, all 
but one Prx use TRX to restore the original thiolate (see fig 2C). 
 
Redox signaling and its effect on signaling pathways  
Oxidative and reductive stress can induce redox surges with a resultant change in the 
thiol status of the proteins. Post-translational modifications of proteins or changes in the 
thiol status of proteins due to changes in the redox environment of the cell are two of the 
major pathways for signaling in cells. Characteristically, changes in the cellular redox 
environment could result in modification of signal transduction, DNA and RNA 
synthesis, protein synthesis, enzyme activation, as well as regulation of the cell cycle153-
155;156;157;137, 158, 159. 
 
A number of studies have shown that ROS and RNS have the ability to change or modify 
several signaling pathways72, 160-165, 165. Among these pathways are the mitogen-activated 
protein kinases (MAPK), which has been shown to be activated by both exogenous, and 
receptor stimulated H2O2166; Protein tyrosine phosphatases (PTPs) and  thioredoxin 
(TRX). Modification of signaling pathways is possible because certain key proteins such 
as PTPs and TRX contain essential cysteines which serve as targets for ROS and RNS167, 
168. Transcription factors like  AP-1 and NF-kB, and Caspases  are considered redox 
sensitive because it has been biochemically demonstrated that their critical cysteines are 
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in the thiolate form accounting for the ease with which they are oxidized and reduced by 
oxidants and enzymes169-171. 
 
The first evidence of reversibility of thiols oxidized by ROS and RNS was demonstrated 
with PTPs at a time when PTPs were first recognized as important players in signaling. 
Over the years, redox-mediated regulation of PTPs has been supported by several in vivo 
studies. The following PTPs are known targets for ROS and RNS, PTP1B, SHP-2, 
LMW-PTP, PTEN as well as CDC25172. 
 
ROS induces the oxidative modification of Protein tyrosine phosphatases (PTPs)  
Protein tyrosine phosphatases (PTPs) are important enzymes in the control of cell cycles 
and signal transduction. They act in conjunction with protein tyrosine kinases to regulate 
the phosphorylation of protein tyrosine in response to cellular signals173, 174. Many studies 
have revealed that PTKs may be directly activated by the inhibition of PTPs by ROS 167, 
175, 176. Reversible inactivation of PTPs by ROS (especially H2O2) plays an important role 
in redox control and cell signaling132. Based on the work done by Rhee’s laboratory, we 
now know that stimulation of A431 cells with epidermal growth factor (EGF) leads to the 
generation of H2O2 and a consequent inhibition of PTP1B70. Other biochemical studies 
also showed that an increase in the production of intracellular oxidants could contribute 
to enhanced tyrosine phosphorylation-dependent signaling, such as signaling in response 
to growth factors70;66, by transiently stemming the enzymatic activity of members of the 
PTP family, and promoting a burst of PTK activity177, 178. However, it is unclear if this 
phenomenon is the same for every member of the PTP family. 
 25 
 
ROS and the cellular redox state are able to regulate the activity of PTPs. PTPs have a 
functional motif that contains a constant cysteine residue, which acts as an electron donor 
in catalysis179, 180. As a result of its unsually low pKa, the functional cysteine residue is 
prone to oxidation and thus inactivation. Only oxidations that do not advance beyond 
sulfenic acid (S–OH) are reversible181, 182. A vital requirement for regulating the activity 
of PTPs (or any regulating molecule) is that the modification be specific and reversible. 
However, the cysteine sulfenic acid formed at the active site of phosphatases can be 
oxidized further to non-reversible cysteine-sulfinic acid and cysteine-sulfonic acid, within 
the cell 183. This effect is believed to be countered by glutathionylation184.  
 
Glutathionylation is a reaction of either cysteine or cysteine sulfenate with GSH within 
the cell to form a mixed disulfide bond. The formation of a mixed disulfide between 
PTP1B and GSH (or GSSG) would prevent irreversible oxidation of the active site 
cysteine and provide for the reversible reduction either chemically or enzymatically. 
Barrett et al. 185 have reported that PTP1B is inactivated by the formation of a mixed 
disulfide with glutathione and that this inactivation is reversed not only by DTT but also 
more importantly by thioltransferase, a thiol-disulfide oxidoreductase that is specific for 
glutathionyl mixed disulfide substrates186, 187 and specifically utilizes GSH as co-
substrate188. The glutathionylation occurs on Cys215, the active site cysteine. This 
mechanism suggests an alternative modification to the redox regulation of cysteine in 
PTP1B and suggests a possible in vivo mechanism in the regulation of phosphatase 
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activity. Also, reversible S-glutathionylation also appears to form the basis for redox 
regulation of c-Jun DNA binding169.  
 
PTP-1B is directly inactivated by ROS-induced reversible oxidation of its catalytic site, 
Cys215, and this has been proposed as a mechanism for EGF-mediated mitogenic 
signaling151; 189. Studies on B lymphocytes reveal that, following B cell receptor 
activation, the ROS produced by DUOX1 enhance prompt generation of a signal by 
reversible inhibition of SHP1, which then results in enhanced tyrosine phosphorylation 
and activation of Lyn kinase 190. Superoxide radical has been shown to regulate the 
activity of PTPs (especially PTP1B) very efficiently, again through cysteine residues 132.  
 
Phosphatase and Tensin Homologue (PTEN) and Reactive Oxygen Species 
The tumor suppressor PTEN (phosphatase and tensed homologue) regulates cell growth, 
survival and migration by the removal of the 3’-phosphate of phosphoinositides. It has 
been reported that the exposure of cells or purified PTEN to H2O2 resulted in inactivation 
of PTEN in a time- and H2O2 concentration-dependent manner 167, 189, 191. As with other 
phosphatases, H2O2 induces the reversible inactivation of PTEN through oxidation of the 
essential Cys124 167; 192. This forms cysteine-sulfenic acid, which reacts with the so-
called backdoor cysteine (Cys71 substrate) to form a disulfide. The disulfide formed is 
then further reduced to its active form by thioredoxin (TRX)193. 
 
Though the stimulation of various receptors induces H2O2 production, Lee et al.194 
proposed that the receptor-mediated activation of phosphoinositide 3-kinase (PI3K) alone 
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does not does not account for the accumulation of 3'-phosphorylated phosphoinositides, 
and that the simultaneous inactivation of PTEN by H2O2 produced in response to receptor 
stimulation might also be essential for this event195. A high frequency of PTEN mutations 
and subsequent loss of function has been reported in several tumor types like endometrial 
carcinoma, brain, and breast cancer196. It is documented the loss of PTEN function results 
in an increased Akt activity and, subsequently, cell survival197. Evidence exists that 
inactivation of PTEN by oxidation might be a physiological mechanism for regulation of 
this enzyme, not only by oxidative stress, but by ROS produced in other circumstances 
such as the stimulation of cells by growth factors 198, 199.  
 
The cyclin-dependent kinase inhibitor p27Kip1, a target of Akt, has been proposed as a 
downstream mediator through which PTEN may positively regulate cell cycle 
progression200. In prostate cancer, 16–68% of the cases show an association between the 
low grade expression or loss of p27 protein with either adverse or impaired prognosis201-
204;205.  
 
CDC25 Phosphatases and Reactive Oxygen Species 
Cdc25 phosphatases also known as the dual-specificity phosphatases, are key activators 
of the CDK/cyclin complex, hence they serve as regulators of normal cell division. There 
are three isoforms of Cdc25, namely Cdc25A, Cdc25B, and Cdc25C. These three 
phosphatases function to dephosphorylate the CDK/cyclin complex on pThr14 and/or 
pTyr15 residues, counteracting the phosphorylating effect of the Weel and Myt1 kinase. 
This dephosphorylation prompts the ultimate activation of CDK/cyclin activity during 
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normal cell cycle progression206, 207. Cdc25A controls both the G1-to-S and G2-to-M 
transitions, whereas Cdc25B and Cdc25C are regulators of the G2-to-M transition.  
 
The Cdc25 phosphatases also play an important role in the checkpoint response that 
prevents CDK/cyclin activation following DNA damage208, 209. Confirming an important 
role for the Cdc25 phosphatases in cancer, Cdc25A and Cdc25B, but not Cdc25C, are 
over expressed in many different primary human cancers210.  
 
Like all other PTPs Cdc25 phosphatases have two cysteine molecules in their functional 
site. One of the cysteines exists in the very reactive thiolate (S-) form while the other one 
exists as a less reactive thiol. The thiolate in Cdc25’s functional motif has been shown to 
be oxidized by low concentrations of ROS resulting in the formation of a reversible 
cyseine-sulfenic acid (see eqn 13). The resultant sulfenic acid then forms a mixed 
disulfide bond with the second thiol to prevent further oxidation by ROS to an 
irreversible sulfinic acid. The reduction of the disulphide bond to the original thiolate is 
carried out by either TRX or GSH. H2O2 causes oxidation of the active site cysteine 
residue in Cdc25- PTP, with a subsequent binding to 14-3-3 proteins for nuclear export 
and subsequent degradation211; 212, 213.  Oxidative stress has also been shown to induce the 
nuclear export of Cdc25B through protein kinase B/Akt-dependent phosphorylation on 
Ser353 214. 
 
An association between mitogenic signaling and the cell cycle mechanism has been 
suggested by studies which showed that the tyrosine phosphatase Cdc25A, among others, 
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could have an effect on Raf-1, a key component of the MAPK pathway215, 216. In 1995, 
Conklin et al. showed that Raf-1, which is known to bind 14-3-3 proteins, appeared to 
associate with Cdc25A and stimulate its phosphatase activity217. Galaktionov et al. 218 
also showed an association between the Cdc25 phosphatase and Raf-l in somatic 
mammalian cells and in meiotic frog oocytes. These authors also suggested that 
activation of the cell cycle by the Ras/Raf-l pathways might partially be mediated by 
Cdc25. Another study also showed that dephosphorylation of Raf-1on tyrosine by 
Cdc25A resulted in a significant decrease in the kinase activity of Raf-1219, and 
consequently of ERK. On the flip side, this implies that inactivation of CDC25A could 
lead to an increase in the kinase activity of Raf-1 and thus the phosphorylation and 
activation of ERK. 
 
Recently, a study by Vogt et al.220 showed that overexpression of Cdc25A in whole cells 
resulted in the dephosphorylation of ERK, which was reversible by an inhibitor of 
Cdc25A (2-mercaptoethanol)-3-methyl- 1,4-naphthoquinone  (compound 5). The high 
point in this study is that a Cdc25 inhibitor increased phosphorylation and nuclear 
accumulation of ERK thereby underscoring the proposition that Cdc25A regulates the 
phosphorylation state of ERK. More recently, in addition to showing a physical 
interaction between Raf-1 and Cdc25A, Nemoto et al. 221 were also able to show that the 
phosphatase Cdc25A regulates Raf-1/MEK/ERK kinase activation in human prostate 
cancer cells. Additional work done by Wang et al.222 suggested that phospho-ERK is 
possibly another substrate of Cdc25A. Based on the above studies, one can infer that the 
oxidation (downregulation) of CDC25A by ROS (which renders Cdc25A inactive) may 
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also result in the phosphorylation of ERK that could ultimately phosphorylate a number 
of transcription factors, as well as the CDK inhibitor p27. 
 
Mitogen Activated Protein Kinase- Phosphatase (MKPs) and Reactive Oxygen 
Species 
These are dual specificity phosphatases which have the ability to inhibit the mitogen 
activated protein kinases (MAPKs) in several cell types223-229. Like other dual specificity 
phoshatases, mitogen activated protein kinase phosphatases (MKPs) have recently been 
added to the redox sensitive phosphatases list. Seth and Rudolf 230  showed that, like 
other PTPs, MKPs are able to form cysteine-sulfenic acid upon oxidation by ROS. Unlike 
other PTPs, however, the sulfenic acid formed does not form a disulfide with proximate 
cysteine or sulfenyl amide bond species with neighboring residue, but rather utilizes 
various cysteines distributed in both the N-terminal substrate-binding domain (Cys147 in 
particular) and the C-terminal catalytic domain (Cys218) to protect its active site from 
further oxidation. 
 
MAPKs play a central role in mediating intracellular signaling events triggered by 
mitogens, growth factors, and stress231, 232. The MAPKs are activated by specific 
upstream dual specificity kinases (MAPK kinases, MKKs) through phosphorylation on 
both threonine and tyrosine residues in the TXY motif. Extracellular stimuli activate 
MAPKs leading to the phosphorylation of an array of cellular substrates and nuclear 
transcription factors.  
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In mammals, three distinct MAPK families have been studied extensively. The 
extracellular signal-regulated kinase (ERK) family is activated by growth and 
differentiation factors and by phorbol esters 233. The c-Jun NH2-terminal kinase (JNK) 
family (or stress-activated protein kinase (SAPK) and p38 MAPK families are activated 
by pro-inflammatory cytokines and environmental stress. It is noteworthy that the three 
aforementioned subgroups of MAPKs have been implicated in both cell growth and cell 
death, hence the need to tightly regulate these pathways is principal in determining cell 
fate234. Therefore the injurious effect of non-stop activation of MAPK pathways may 
include excessive production of MAPK-regulated genes, uncontrolled proliferation, and 
unscheduled cell death 235. 
  
A number of cellular stimuli that induce ROS production are also capable of activating 
MAPK pathways concurrently, in multiple cell types. This was established by studies 
which showed that prevention of ROS accumulation by antioxidants blocks MAPK 
activation after cell stimulation with cellular stimuli235-237. Additionally, it has been 
documented that direct exposure of cells to exogenous H2O2, to imitate oxidative stress, 
resulted in the activation of MAPK pathways238, 239. Though the mechanism(s) by which 
ROS can activate the MAPK pathways, is still not well defined and because ROS can 
change protein structure and function by modifying critical amino acid residues of 
proteins7, 238, 239, we could therefore infer that the oxidative modification of signaling 
proteins by ROS may a probable mechanism for the activation and or inactivation of 
MAPK pathways. 
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The Effect of ROS on Transcription Factors 
AP-1 and NFκB  
The tumor progression stage of carcinogenesis has been shown to be modulated by 
transcription factors such as activator protein-1 (AP-1) and nuclear factor-kappaB 
(NFκB). A causal relation has been well documented between neoplastic transformation 
and transcription factor AP-1 transactivation 240-243. Infact, a constitutive increase of AP-1 
activity has been associated with the malignant conversion of papillomas to carcinomas 
244. There is an increase in NFκB transactivation during tumor progression 245.This NFκB 
transactivation is also increased by agents that elevate AP-1 activity during tumor 
progression while its inhibitors also attenuate AP-1 activity 246, 247 suggestive of common 
upstream signaling cascades that mediate elevated AP-1 in addition to NFκB 
transactivation during tumor progression. 
 
ROS have been shown to act as activators of transcription factors which modulate their 
activity either directly or indirectly by activating other signaling cascades. NFκB 
transactivation is considered redox sensitive because (i) The phosphorylation of its 
inhibitor I-κB is mediated by oxidation; and (ii) the Ref/thioredoxin-dependent binding of 
the p50 subunit to the DNA is controlled by the reduction of an essential cysteine group 
248 (cite article). NFκB activation can be be induced by several activators/oxidants in the 
absence of any physiological stimulus and is inhibited by a wide range of antioxidants 249-
251. On the other hand AP-1 DNA binding activity has also been shown to be modulated 
by Ref/thioredoxin-dependent reduction of cysteines in c-Jun and c-Fos 252.  
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Persistently high ROS levels activate redox-sensitive transcription factors, such as 
nuclear factor-kappaB (NF-κB) and activator protein-1 (AP-1), which may then act as 
molecular switches that convert normal cells into premalignant cells, with ensuing clonal 
expansion to form solid tumor253. Hence, abnormal activation of NF-κB and AP-1, which 
results in the transcriptional activation of genes involved in inflammation, cellular 
proliferation, and growth, has been implicated in pathophysiology of various 
malignancies 253, 254.  
 
Mitogen-activated protein kinases (MAPKs) have been shown to modulate transcription 
factor activities in addition to being part of kinase cascades that serves as transmitters 
connecting extracellular stimuli to specific transcription factors thus allowing these 
signals to regulate specific gene expression. Studies have shown that JNKs and p38 
MAPK are a part of the stress response pathways activated by cellular stress induced by 
agents like heat, UV and ionizing radiation and inflammatory cytokines mediating 
inhibition of cell proliferation or cell death 255, 256. AP-1 activity has been shown to be 
modulated by MAPKs in response to various stimuli257. NFκB activation has been 
reported to be modulated by MEKK1, a kinase upstream of JNKs 258 as well as p38 
MAPK 259. There is evidence that antioxidants can attenuate MAPK activation 6, 255, 260, 
thereby suggesting that MAPK signaling cascades are additional targets affected by ROS 
levels in cells. 
 NRF-1  
Nuclear respiratory factor 1(NRF-1) is a protein that encodes genes that code for a 
phosphorylated nuclear protein with a bZIP domain. The encoded protein forms a homo- 
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or heterodimer, which functions as a transcription factor that activates the expression of 
some key metabolic genes. These key metabolic genes regulate cellular growth and 
nuclear genes required for respiration, heme biosynthesis, mitochondrial DNA 
transcription and replication261, 262 Initially, NRF-1 was described as an activator of 
cytochrome c expression and afterwards was found to act on many nuclear genes essential 
for mitochondrial respiratory function263, 264 such as genes encoding respiratory subunits 
265, the rate-limiting heme biosynthetic enzyme266 as well as mtDNA transcription and 
replication factors267, 268. 
 
NRF-1 binds to the antioxidant response element (ARE) in the promoters of genes which 
are involved in response to cellular stress269 to induce the expression of phase II 
detoxifying enzymes and oxidative stress-inducible proteins, like NADPH, quinone 
oxidoreductase, and glutathione S-transferaseA2 270, 271. Studies have shown that NRF-1’s 
ability to regulate the ARE of stress-related genes and TNFα is based on its interaction 
with transcription factors such as AP1 proteins (c-Jun, JunB, and JunD)272, 273. In 
addition, NRF-1 has been shown to play an important role in cellular growth and 
differentiation274, 275.  A biochemical study by Chang et al276. implicated NRF-1 protein 
with the regulation of neurite outgrowth.  
 
Studies have shown that NRF-1 is phosphorylated both in vivo and in vitro on serine 
residues within a concise amino-terminal domain277. The phosphorylation of these sites in 
vitro augments NRF-1 DNA binding action, surmising the capacity of such modifications 
to regulate NRF-1 function. Herzig et al.278 showed that the activity of NRF-1 is 
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enhanced by phosphorylation, which occurs in cells that have been stimulated with 
serum. It is assumed that a phosphorylation such as this allows the nuclear transcriptional 
apparatus to respond both to extracellular signals and intracellular ATP concentrations in 
controlling the expression of the respiratory chain278. The post-transcriptional 
modification of the N-terminus of NRF-1 has been shown to play an important role in 
controlling DNA-binding activity277. It has been established that P/CAF, which is a 
p300/CBP (cAMP response-element-binding protein (CREB)-binding protein)-associated 
factor, can interact directly with the N-terminal domain of NRF-1 and modify it by 
acetylation. The ensuing modification significantly stimulates the DNA-binding activity 
of NRF-1279. A study by Cho et al.280 showed that the methylation on the NRF-1 sites 
may be a means of silencing the Tfam promoter with an ensuing decrease of 
mitochondrial biogenesis281. According to Narayanan et al.282 NRF-1 often exists as a 
complex with Keap1 (inhibitor) but as a result of stress, NRF-1 separates from Keap1 and 
becomes active. 
 
NRF-1 and 17 β-Estradiol (E2) 
Estrogen increases the transcription of NRF-1283, 284. Results of work done by Rodríguez-
Cuenca et al.285 show that E2 appears to affect the mitochondrial biogenic program in two 
ways. The first is inhibiting it through the downregulation of NRF-1, gabpa, and tfam 
mRNA286; or second, downregulating PTEN mRNA levels in cell-cultured brown 
adipocytes, implying an activation of the PI3K-Akt pathway and therefore a 
mitochondrial recruitment-stimulatory signal. E2 has been shown to inactivate PTEN 
activity by phosphorylation and, hence, influence PTEN activity, suggesting both a 
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chronic and an acute control mechanism of PTEN by estrogens 287. Felty et al. 288 showed 
that E2-induced oxidants increase the transcriptional activity or binding of AP-1, CREB, 
and NRF-1 to their individual DNA response elements. The study actually showed that at 
physiological concentrations E2 stimulates a rapid production of intracellular ROS 
resulting in the phosphorylation of c-jun and CREB as well as increased activity of 
redox-sensitive transcription factors NRF-1, c-jun, and CREB, which are known to be 
involved in the regulation of cell cycle genes289. 
 
NRF-1 and Cancer 
Xu et al. 290 have been able to demonstrate a connection between cancer and NRF-1, 
based on the result of a study which observed changes in NRF-1LKO (NRF-1 liver 
knock-out ) livers. The livers were characterized initially by cell death, proliferation, and 
inflammation, followed by the appearance of dysplastic cells and eventually cancer. The 
X gene of hepatitis B virus (HBV) which is one of the chief factors in HBV-induced 
hepatocarcinogenesis is necessary to achieve a productive HBV replication in vivo. 
Recently, Tokosumi and others291 showed that NRF-1 exclusively binds the 21-bp 
minimal promoter and contributes to transcription of the X gene. They also suggested that 
concurrent activation of the X gene and mitochondrial genes by NRF-1 may allow the X 
protein to target mitochondria most efficiently292. A study by Auf dem Keller et al. 293 
showed that NRF-mediated gene expression in keratinocytes is dispensable for wound 
healing but crucial for skin tumor prevention. 
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NRF-1 and cell cycle 
The transition of cells from quiescence (G0) to proliferation (G1) increases the cellular 
energy (ATP) demand. The cell responds to this increase in demand for ATP by 
modulating the activity of the respiratory chain components, and it is the duty of NRF-1 
to regulate the expression of a number of genes required for mitochondrial respiratory 
function 264.  
 
A recent study demonstrated that NRF-1 activity is enhanced by phosphorylation upon 
serum-induced proliferation, leading to transcriptional induction of cytochrome c, a major 
component of the respiratory apparatus294. The induction of cytochrome c was associated 
295 with enhanced energy production by the mitochondria in preparation for entry to the 
cell cycle. 
 
Results from work done by Herzig et al. 296 show that NRF-1 functions to induce gene 
expression and maintain the level of cytochrome c in actively dividing cells. Additionally, 
the results also suggested the possibility that activated NRF-1 may contribute to the 
synthesis of other respiratory chain constituents later in the cell cycle. It can therefore be 
inferred that the phosphorylation of NRF-1 may be a significant regulatory event in the 
transition from quiescence to active cell division. 
 
Virbasius et al. 297 showed that NRF-1 sites are found in genes that may be directly 
involved in cell cycle regulation (like cdc2, RCC1) or are regulated by cell growth (like 
omithine decarboxylase, DNA polymerase-a, and GADD153). Their study concluded that 
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even though the most current and best defined biological role for NRF-1 is in the nuclear 
control of mitochondrial function, the NRF-1 protein or related proteins having the NRF-
1 DNA-binding domain may possess the ability to integrate various functions required for 
cell maintenance, growth, and proliferation.298 
 
NRF-1 has been shown to mediate the apoptotic function of c-myc in a study which also 
shows that cytochrome c and other nuclear-encoded mitochondrial genes are also 
regulated by NRF-1 and provides evidence of a link between the induction of NRF-1 
target genes and sensitization to apoptosis on serum depletion299. The finding by Felty et 
al. 300 that E2-induced mitochondrial ROS control the expression of early G1 phase genes 
(Felty and Roy, unpublished results), imply that E2-induced ROS increase the 
transcriptional activity or binding of AP-1, CREB, and NRF-1 to their respective DNA 
response elements responsible for the expression of early cell cycle genes. Based on 
previous studies (already mentioned in this review) which showed that redox-sensitive 
transcription factors c-jun, CREB, and NRF-1 regulate cell cycle genes262, 301, 302, Felty et 
al.’s finding could be a pointer that E2-induced ROS may play a role in cell cycle 
progression of estrogen-dependent cells 303. 
 
NRFI and ROS 
A study by Suliman et al.262 showed that ROS signaling is necessary for hepatic 
mitochondrial biogenesis accompanying cell proliferation, which is linked to activation of 
pro-survival PI3K-Akt pathways. The PI3K-Akt pathway in turn leads to NRF-1 
activation and subsequent DNA binding. Furthermore, ROS originating in mitochondria, 
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cytoplasm, or outside the cell could activate Akt and promote NRF-1 translocation. 
Hence, PI3K-Akt activation may regulate both mitochondrial biogenesis and cell 
proliferation after oxidative stress.  
 
Already mentioned in this review is the fact that cysteine-dependent phosphatases, like 
PTEN, which are reciprocal regulators of PI3K, are sensitive to inactivation by oxidants. 
This is substantiated in a recent study by Piantadosi and Suliman 304, which provided 
evidence that the stimulation of PI3K by extracellular oxidants activate Akt and promote 
NRF-1 phosphorylation as well as nuclear translocation. NRF-1 phosphorylation 
increases its ability to stimulate transcription of Tfam, a downstream nuclear-encoded 
gene for a mitochondrial protein required for mtDNA transcription and replication. 
  
Based on work done on HeLa cells, Miranda et al.305 have been able to show that cells 
depleted of mitochondrial DNA (ρ0) have an increased amount of intracellular ROS, and 
that under these conditions, NRF-1 and Tfam are up regulated, further supporting the 
postulated role of ROS in mitochondrial signaling to the nucleus. NRF-1 has also been 
found to play a role in the regulation of genes involved in glutathione synthesis, therefore 
signifying a basis for an equally low GSH concentration and reduced stress response in a 
study which also found that interference with the NRF-1 gene results in hypersensitivity 
of fibroblasts to the noxious effects of various oxidizing agents306. Work done by Chen et 
al. 307 showed that NRF-1 may be required to protect fetal liver cells from endogenous 
TNF-induced apoptosis. The study concluded that NRF-1 plays an important role in 
maintaining redox balance in the fetal liver cells signifying a cell-specific and 
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developmental stage-specific function of NRF-1 in protecting liver cells from apoptosis 
during development. 
 
Cell Cycle 
Cell cycle control 
Simply put, a cell cycle refers to a programmed life cycle of a dividing cell. The process 
of cell-cycle transition can be divided into four phases: the G1 phase, where mRNA and 
proteins are synthesized in preparation for DNA synthesis; the S phase where DNA 
synthesis occurs; the G2 phase, where mRNA is synthesized in preparation for the fourth 
phase, mitosis (M phase). Quiescent cells are found in the G0 phase and exhibit minimal 
mRNA and protein synthesis. Stimulation of quiescent cells (G0) results in their entry 
into the G1 phase which in turn induces a number of proteins that regulate and control 
cell growth and proliferation 229;308.  
 
In addition to the four cell cycle phases, there are two main checkpoints that regulate cell-
cycle progression. The G1/S checkpoint prevents the replication of damaged DNA. This 
checkpoint is regulated by a balance between growth-stimulating and growth-inhibitory 
responses. The second checkpoint, which is G1/S to G2/M checkpoints control the 
sequence and timing of cell-cycle transitions, enabling the assimilation of cell division 
with environmental stimuli as well as the monitoring of DNA damage to maintain 
genomic integrity. An additional spindle assembly checkpoint functions to delay mitosis 
until the mitotic spindle is correctly formed 309.  
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The cell cycle process is controlled by the following proteins: The cyclins, namely 
cyclins A, D, and E; the cyclin dependent kinases CDK2, 4, and 6; the cyclin kinase 
inhibitors (CKIs), namely p16INK4a (p16), p21CIP1/WAF1(p21), and p27; and other negative 
regulators such as the retinoblastoma protein (Rb) and p53, which regulate the effects of 
both CKI p21 and cyclin A protein310. During the G1phase, cyclins D1 and E are rapidly 
synthesized and bind to CDK4 and CDK2, respectively. The resulting cyclinD-CDK4/6 
complex then phoshorylates the retinoblastoma protein (Rb). Phosphorylation of Rb 
releases E2F which mediates gene expression and the induction and the formation of 
cyclin E- CDK2 complex.  
 
The cyclin E- CDK2 complex phosphorylates a broad variety of proteins, including Rb 
with a consequent release of E2F, which promotes cell-cycle progression to late G1, 
leading to the induction and formation of the cyclin A/CDK2 complex.  
 
The cyclin A/CDK2 complex functions to advance cell-cycle progression through the 
G1/S phase, into S, as well as late S and S/G2 interphase (cyclin A/CDK1). Cyclin 
A/CDK1 collaborates with Cyclin B/CDK1 to regulate G2 to M phase transition. In its 
phosphorylated state, cyclin B complex is inactive and requires dephosphorylation on Tyr 
15 by CDC25 to activate it. The active cyclin B complex promotes cell division (M 
phase)229. 
 
The active cyclin D complex is inhibited by CDK inhibitor p16 to induce early G1 arrest 
and prevent the phosphorylation of Rb. It has also been shown that •NO has the potential 
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to induce p21, leading to the inhibition of the action of cyclin E complex. Proliferating 
cell nuclear antigen (PCNA), a cofactor for DNA polymerase is negatively regulated by 
p21 311. Inhibition of CDK2 activity by p27 can prevent the phosphorylation of 
transcription factors critical for entry into the S phase 312. In G2, p53 can induce late G2 
arrest (inhibition of active cyclin B action) or mediate early G2 arrest via p21 inhibition 
of Cdc25.  
 
The role of p27 in cell cycle control 
The CDK inhibitor p27 has a negative effect on the activity of CDK2-cyclin complexes 
during G1 phase and CDK1 (Cdc2) complexes during G2 phase. In breast cancer, cyclins 
D1 and E, in addition to the cyclin-dependent kinase inhibitors p21 and p27, play very 
important roles in cell-cycle control and as potential oncogenes or tumor suppressor 
genes. Reduced expression of p27 has been associated with the poor survival of cancer 
patients313. 
In breast cancer cells, CDK inhibitors are regulated following mitogenic stimuli such as 
activation of receptor tyrosine kinases and steroid hormone receptors. Their deregulation 
frequently impacts on breast cancer outcome, including response to therapy314. The 
expression of p27 is regulated through transcriptional and translational control 
mechanisms, by modulation of both protein stability and changes in subcellular 
localization. 
 
According to Medema et al. 315, even though the transcription of the p27 gene is regulated 
by factors like AFX-like Forkhead transcription factors, the abundance of p27 during the 
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cell cycle is mostly mediated post-transcriptionally. As cells exit quiescence and progress 
into S phase, the levels of p27 protein decline as a result of decreased translation of p27 
mRNA and targeted proteolysis316. 
 
In the G1 and S phase, degradation of p27 is regulated by two RING-finger E3 ubiquitin 
ligase-containing complexes with contrasting subcellular locations. These complexes 
respectively ubiquitylate p27 and target it for proteosomal degradation. In addition to 
promoting p27 degradation, phosphorylation also regulates p27 subcellular localization. 
Following mitogen stimulation, this p27 is likely to be phosphorylated on serine 10 by 
human kinase-interacting stathmin (hKis), which promotes nuclear export317. According 
to work done by Liang and Slingerland, 318 p27 is also phosphorylated on two threonine 
residues, Thr157 and Thr198, by Akt, which results in the cytoplasmic retention of p27 . 
The resultant cytoplasmic localization following the phosphorylation of p27 at Thr157 is 
due to inhibition of its nuclear import. Overall, this suggests a model in which mitogenic 
signaling pathways promote cytoplasmic localization of p27 and its subsequent 
degradation by the Kip1 ubiquitination-promoting complex (KPC). This will increase the 
activity of nuclear cyclin E-CDK2 resulting in p27 Thr187 phosphorylation and 
degradation of p27, leading to a positive feedback loop for enhancement of cyclin E-
CDK2 activity. 
 
Sakakibara et al. showed that the ERK subfamily of MAPK is both essential and 
adequate in the regulation of p27 and a number of other studies have also established that 
ERK activity also contributes to the down-regulation of p27 319; 320-324. 
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The effects of ROS on regulators cell cycle  
There is increasing evidence suggesting that ROS and RNS play a part in the regulation 
of cell proliferation and cell-cycle control. Studies have shown that there is a significant 
similarity between the pathway that regulates cell cycle progression and the one that 
regulates the induction of apoptosis. These similar pathways are intimately 
interconnected by critical regulatory molecules and signal transduction cascades325.  
 
Reactive oxygen and nitrogen species have a wide range of effects on cell-cycle 
advancement. The growth-inducing actions of ROS/RNS may be exerted via the 
activation of kinase signaling cascades, redox regulation of tyrosine phosphatases, and 
direct activation of transcription factors144. 
 
Low concentrations of H2O2 increase cell proliferation through increased cyclin D 
expression and G1/S transition in fibroblasts326 and by means of decreased expression of 
p27 in prostate tumor spheroids327. Arnold et al. 328 have also shown that H2O2 mediates 
cell growth and cell-cycle regulation caused by targeted overexpression of the Nox1 
subunit of the NADPH oxidase328. The ability of ROS to promote the G1/S transition is 
further substantiated by the finding that treatment with antioxidants will repeatedly block 
proliferation and cell-cycle progression. This can be corroborated by the work of Menon 
et al. 329, which showed that the antioxidant N-acetyl-L-cysteine induces G1 arrest by 
decreasing cyclin D1, increasing p27 protein levels, and leading to hypophosphorylation 
of Rb329. It is also noteworthy that low to moderate ROS can induce MAPK pathways 
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that lead to cell growth and proliferation, whereas high ROS induce DNA damage and/or 
MAPK pathways that activate p53, cell arrest, and apoptosis326. 
 
Growth arrest associated with higher, sustained levels of ROS and RNS appears to 
involve the induction of inhibitory cell-cycle control proteins, especially p21, and the 
repression of cyclins330. More recently, the redox-sensitive family of Forkhead box class 
O (FOXO) transcription factors has been shown to promote cell-cycle arrest in G1 by 
transcriptional up-regulation of the CDK inhibitor p27 and down-regulation of cyclin 
D1331. 
 
Very little is known about the redox control of the spindle assembly checkpoint. It has 
recently been suggested that mitotic spindle pole formation is an important component of 
H2O2 -induced mitosis in type II pneumocytes 332. Cdc2 and other mitotic protein kinases 
have also been shown to play a role in spindle regulation,333 suggesting a possible role of 
redox control of Cdc2 activation by Cdc25C in the spindle checkpoint. The MAPK 
pathways, especially p38 and ERK1/2 ,334 which are regulated by ROS appear to play a 
key role in mitotic spindle assembly. 
 The role of Redox signaling in Anti estrogen Resistance   
Based on the above review, we may therefore infer that redox signaling could contribute 
to anti-estrogen resistance by the following biological processes: induction of ROS by 
anti-estrogens and a subsequent inactivation of PTPs or MKPs resulting in the activation 
and hyper-stimulation of either the MAPK pathway or the PI3K/Akt pathway, which 
could either affect the cell cycle through the activation of transcription factors or the 
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CDKI leading to a change from the tamoxifen sensitive phonotype to a tamoxifen 
resistant one. 
 
Cancer cells are characterized by uncontrolled proliferation and altered energy 
metabolism. In response to the activation of many oncogenes, continuous mitogenic 
signaling augments the production of ROS. Additionally, mitogens like estrogen and anti-
estrogens such as tamoxifen have been shown lead to ROS production when they are 
exposed to cancer cells both in vitro and in vivo. The ROS and redox signaling that ensue 
result in the induction of replication stress and DNA damage response, which in 
conjunction with the functional checkpoint, induces senescenes, often considered a 
barrier to tumorigenesis 335, 336.  Interestingly, once cancer cells have escaped the 
mechanisms that counteract mitogenic signaling, they advance to a pro-oxidative state 
typified by unbridled proliferation and altered energy metabolism, including defects in 
mitochondrial respiration. 
 
Defects in mitochondrial respiration cause inactivation of PTEN in a redox-dependent 
manner and activation of the pro-survival factor Akt 337. Akt is one of the kinases that 
phosphorylate p27 on the threonine 157 position resulting in cytoplamic sequestration of 
p27 with an ensuing loss in its cyclin kinase inhibitory function; a consequent 
unrestrained cell proliferation and a change from a tamoxifen sensitive to a tamoxifen 
resistant phenotype. Futhermore, activated Akt has been shown to phosphorylate the 
redox sensitive transcription factor NFR-1 thereby activating it and leading to its binding 
to the promoter region of  cell cycle genes338. 
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It is also probable that NRF-1 could be part of a pathway that connects the mitogen-
activated signaling cascade (either the MAP kinase or the PI3K Akt pathway) to cell 
cycle progression. Following ROS production and the induction of a pro-oxidative state 
in cancer cells, PTPs are oxidized in a redox dependent manner, rendering them unable to 
carry out their usual function. In the case of Cdc25A this function is to inactivate the 
MAPKKK Raf-1, with which it has been shown to have an on/off switch like 
relationship339. The inability of oxidized Cdc25A to inactivate Raf-1 results in a 
continuous activation of the MAP kinase pathway, with a consequent upregulation and 
nuclear translocation of ERK. The nuclear translocation of ERK enables it to 
phosphorylate NRF-1 protein causing it to bind to the promoter of certain cell cycle genes 
(unpublished work done in Dr Roy’s lab) inducing their transcription and promoting cell 
proliferation.  
 
Tumor suppressor genes also play an important role in linking metabolism to cell growth. 
A central regulator of metabolism is the PI3K/AKT pathway, which controls metabolism 
through several mechanisms, including enhancement of protein translation through 
mTOR340. The c-Myc oncoprotein also plays a vital role in regulating metabolic changes 
required for cell division341. Furthermore, the pro-oxidative state of cancer cells is 
typified by adjustive responses that include changes in the expression of antioxidant 
enzymes and increased production of GSH. Together the interconnected disturbance in 
metabolism and oxidant production common to most tumor cells provide therapeutic 
 48 
opportunities that do not depend on targeting a single oncogene or tumor suppressor 
gene. 
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Figures and Legend 
Figure1-R 
 
Redox reactions involving hydrogen peroxide (H2O2 ) and a thiolate (RS-). Thiolate 
reacts easily with H2O2 forming a sulfenate (RSO-) (see 1A), the sulfenate that is formed 
then reacts with a thiol to form a disulphide bond (see 1B). Then the original thiolate is 
restored by exchange with another thiolate (see 1C). 
 
Figure 2-R 
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The oxidation of Prx by H2O2.  Prx reacts with H2O2 to form a sulfenate (fig.2A). A 
second thiol then reacts with the sulfenate to form an intra-molecular disulphide (fig.2 B). 
In the third and final step, TRX used to restore the original thiolate (fig. 2C). 
 
 
Figure 3-R 
 
Reversible PTP inactivation by H2O2. In step 1, an active PTP containing a thiolate 
reacts with H2O2 to form an inactive but reversible PTP-sulfenate (SO-). In step 2, the 
PTP-sulfenate reacts with GSH within the cell to form a mixed disulfide bond which 
would prevent irreversible oxidation of the active site cysteine and allow for the 
reversible reduction. In step 3, the mixed disulfide bond on the inactive PTP is reversed 
back to a thiolate and PTP becomes active again. 
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Figure 4-R 
 
 
The effect of E2-induced ROS on regular mitogenic signaling. E2 crosses the cell 
membrane and goes to the mitochondrium where it induces ROS formation. The oxidants 
formed inhibit PTEN rendering it unable to inhibit the PI3K/Akt pathway resulting in the 
hyper-stimulation of the pathway and a continuous phosphorylation of Akt. 
Phosphorylated Akt then activates NRF-1 by phosphorylation enabling the now active 
protein to binds to the promoter region of certain cell cycle genes. 
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Figure 5-R 
 
 
The effect of tamoxifen-induced ROS on regular mitogenic signaling. Tamoxifen-
induced oxidants inhibit PTEN rendering it unable to inhibit the PI3K/Akt pathway 
resulting in the hyper-stimulation of the pathway and a continuous phosphorylation of 
Akt. Phosphorylated Akt then activates NRF-1 by phosphorylation enabling the now 
active protein to binds to the promoter region of certain cell cycle genes. 
 
III  REDOX SIGNALING CONRIBUTES TO THE DEVELOPMENT OF 
TAMOXIFEN RESISTANCE IN BREAST CANCER TREATMENT 
Abstract 
Tamoxifen is a selective estrogen receptor modulator (SERM) which is used to treat 
estrogen receptor positive (ER+) breast cancer. It is also used in breast cancer prevention 
 80 
and as an adjuvant in early breast cancer cases. Only about 70% of breast cancer patients 
will initially respond to tamoxifen treatment. About 40% of patients who were initially 
responsive to the drug and majority of the patients with metastatic breast disease will 
develop resistance over time. Therefore the problem of tamoxifen resistance has been a 
major setback in the otherwise successful treatment of ER+ breast cancer patients. 
Although there has been an improvement in our current understanding of the molecular 
mechanism(s) that result in the development of tamoxifen resistance, there is still a lot of 
ground to cover on the subject. In this study we explored the role of Reactive oxygen 
species (ROS) in the evolution of tamoxifen sensitive breast cancer to tamoxifen resistant 
breast cancer. ROS are products of cellular metabolism which have been shown to induce 
oxidative stress. An excessive and/or sustained increase in ROS production has been 
implicated in the pathogenesis of cancer. Furthermore, ROS induced oxidative stress has 
been shown to initiate various cellular responses including cell proliferation and 
transformation; alteration of intracellular redox state and the oxidative modification of 
certain signaling proteins resulting in the post translational modification of their 
downstream targets. Interestingly, like estrogen, tamoxifen has been shown to induce  
ROS formation, making it probable that tamoxifen induced ROS generated as a result of 
prolong tamoxifen treatment of breast cancer patients may play a vital role in the 
development of its resistance. Using tamoxifen resistant LCC2 cell and standard 
laboratory techniques, we examined the role of ROS in the evolution of breast cancer 
from a tamoxifen sensitive phenotype to a resistant one. We were interested in finding 
out how and if ROS induces the post translational modification of p27 resulting in the 
loss of its inhibitory function and if this process can be reversed by pre-exposing the cells 
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to biological or chemical antioxidants. We discovered that, as a result of tamoxifen 
exposure, an increasingly pro-oxidant environment induced cell proliferation by 
diminishing p27 expression and increasing its phosphorylation on Threonine157 and 
Threonine187. This is accompanied by an ensuing reduction of p27 binding to Cyclin 
E/Cdk2 complex and loss of p27 stability culminating in the loss of sensitivity to 
tamoxifen. We also found that Pre-exposing cells to either biological or chemical anti-
oxidants, restored tamoxifen sensitivity by reversing the previous expression and 
phosphorylation of p27.  
   
Introduction 
Tamoxifen resistance has remained a major setback in an otherwise successful treatment 
of estrogen receptor positive (ER+) breast cancer. Most breast cancers are estrogen-
receptor positive (ER+). Approximately 70% of patients with ER+ cancer will respond to 
anti-estrogen therapy, such as tamoxifen1. In addition, a significant number of tumors that 
initially respond to tamoxifen treatment often progress into a resistant phenotype over 
time, in spite of sustained expression of ERα 2, 3. 
 
Over the years, several pathways and postulates have been proposed and examined as 
possible mechanisms of breast cancer resistance to tamoxifen. While some of these have 
translated into beneficial therapies to a large number of patients, tamoxifen resistance still 
remains a significant problem. In addition, though studies have examined the roles of 
ERα and β, and their co-regulatory proteins; growth factor receptors and the activity of 
their downstream kinases; Cas/c-Src/BCAR3 and cell cycle regulators like Cyclins D/E 
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and p27, currently there is no study investigating the effect of Reactive oxygen species 
(ROS) on p27 in tamoxifen resistance.  
 
Cancers have been shown to be under persistent oxidative stress 4. Oxidative stress, 
which is triggered by an imbalance between the production and detoxification of ROS, 5 
has been implicated in the therapeutic resistance to tamoxifen 6. Tamoxifen, a selective 
estrogen receptor modulator (SERM), has been reported to possess both pro- and anti-
oxidant properties. Among its antioxidant actions are: its cardio-protective effect in the 
prevention of atherosclerosis 7, 8; its inhibition of lipid peroxidation 9 and its ability to 
protect low density lipoproteins (LDL) against copper ion-mediated oxidative damage 10 
in humans. Conversely, its pro-oxidant effects include its ability to induce oxidative liver 
damage 11 and its explication as a hepato-carcinogen in rodents due to ROS over-
production that occurs during its metabolism 12, 13. Additionally, it has been suggested 
that oxidative stress might trigger the pathogenesis of tamoxifen-induced toxicity 14. 
Though it has not been ascertained whether the elevated oxidative state of tamoxifen 
resistant breast cancer is due to prolong tamoxifen exposure, the possibility that the pro-
oxidant property of prolonged tamoxifen exposure may play a role in breast cancer 
resistance cannot be ignored. 
 
Reactive oxygen species consist of a number of partially reduced metabolites of oxygen 
such as superoxide anions (O2− •), hydrogen peroxide (H2O2), and hydroxyl radicals 
(OH·), characterized by higher reactivity than molecular oxygen. These reactive species 
are known to play a vital role in cell growth mediated by 17β estradiol (E2) 15. Oxidative 
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stress has been shown to instigate a number of varied responses including cell 
proliferation and transformation. Furthermore, an excessive and/or sustained increase in 
ROS production has been implicated in the pathogenesis of cancer 16. Redox balance is 
achieved by various enzymatic and non enzymatic antioxidant systems that counteract the 
harmful effect of ROS. For example, superoxide dismutase (SOD) catalyses the 
dismutation of the superoxide anion into H2O2, while Catalase and glutathione peroxidase 
(GPx) metabolize H2O2 into water and molecular oxygen 17, 18. It is interesting to note 
that physiological ROS play a significant role in the regulation of signaling pathways 
such as kinase and phosphatase activation/inactivation.  
 
Oxidative stress-induced redox surges could bring about changes in the thiol status of 
signaling proteins with alterations in their Phosphorylation/dephosphorylations functions. 
These modifications could lead to changes in cellular signaling transduction pathways, 
DNA and RNA syntheses, protein syntheses, enzyme activation and cell cycle regulations 
19-27. Signaling proteins such as mitogen-activated protein kinases (MAPK) 27 and protein 
tyrosine phosphatases (PTPs) like PTEN (Phosphatase and tensin homolog deleted on 
chromosome ten) and CDC25 28 have been shown to be susceptible to oxidation because 
they contain essential cysteines which serve as possible targets for ROS in different 
pathways 30, 31.  
   
Protein tyrosine phosphatases (PTPs) are important enzymes in cell cycle control and 
signal transduction. In conjunction with protein tyrosine kinases (PTKs), PTPs regulate 
levels of protein tyrosine phosphorylation in response to cellular signals 32, 33. Many 
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studies have shown that PTKs may be directly activated through the inhibition of PTPs 
by ROS 34, 35. For example, PTEN is a redox sensitive phosphatase which has been shown 
to be inactivated by ROS. The inactivation of PTEN leads to the sustained phosporylation 
and activation of AKT. AKT has been shown to phosphorylate p27 on threonine 157 with 
a resultant cytoplasmic sequestration and a consequent inhibition of its nuclear function. 
 
p27 is a Cyclin-kinase inhibitor (CKI) which was originally discovered as a protein 
whose expression was induced by different growth inhibitory conditions/agents such as 
serum starvation, contact inhibition, transforming growth factor-α or by lovastatin 36. Its 
expression is reduced by mitogens like epidermal growth factors and estrogens. Mice 
with p27 knockout develop multiorgan hyperplasia and pituitary tumors, thus 
underscoring a role for p27 in both proliferation and differentiation 37. p27 is also well-
known for its ability to inhibit G1 Cyclin/CDK complexes. It is noteworthy that its 
activity is regulated by its post-translational modification 38, 39. Hence one may infer that 
because of their capacity to oxidize and inactivate PTEN, ROS may be able to regulate 
p27 function by modulating its post-translational modification. 
 
We therefore hypothesized that (i) in addition to its known action at the ER, tamoxifen 
also prevents estrogen-mediated progression of cell cycle by counteracting estrogen-
induced reactive oxygen species signaling, and (ii) as a result of chronic oxidative stress, 
and the conversion of estrogen-sensitive breast tumors to a tamoxifen-resistant phenotype 
is associated with a progressive shift towards a pro-oxidant environment. Therefore, an 
increase in ROS levels promotes the loss of p27 inhibitory function through the 
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inactivation of protein tyrosine phosphates (PTPs) and a consequent change in p27 
phosphorylation.     
 
To test these hypotheses, we conducted experiments to i) determine the relationship 
between tamoxifen and oxidative stress, ii) determine the effect of ROS on p27 
expression and its phoshorylation in tamoxifen resistant LCC2 cells, iii) determine if pre-
treatment of LCC2 cells with biological or chemical antioxidants can restore tamoxifen 
sensitivity by re-establishing redox balance within the cells, and iv) determine the effect 
of antioxidants on p27 stability and its inhibitory function. 
 
Materials and methods 
Materials  
Antibodies to p27, Cyclin E, CDK2 and Phosphorylated p27 on Threonine187 were 
purchased from Santa Cruz Biotechnology. T157 Phosphorylated p27 antibody was 
purchased from Abcam. Beta Actin, 2', 7’-dichlorodihydrofluorescein diacetate (DCFH-
DA), DMSO, Ebselen and cyclohexamide were purchased from Sigma Aldrich. 
Exactacruz immune- precipitation kit was purchased from Santa Cruz Biotechnology.  
BrdU kit was purchased from ROCHE. Protein A Agarose was purchased from 
Invitrogen. The adenoviruses AdEmpty (EV), AdMnSOD (SOD), and AdCatalase (CAT) 
were purchased from ViraQuest, Inc. (North Liberty, IA, USA).  
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Cell culture 
LCC2 cells were provided by Dr Slingerland (Braman Family Breast Cancer Institute, 
Miami)). Cells were cultured in DMEM (Gibco) containing 5% Fetal bovine serum 
(FBS), 25,000 units of penicillin (base) and 25,000 µg of Streptomycin at 37°C in a fully 
humidified atmosphere of 5% CO2 in air. For experiments, 40% Confluent cells were 
further cultured in DMEM containing 5% Charcoal Stripped FBS for 24hours to 
minimize the effect of serum and synchronize the cells in G1.  Synchronized cells were 
always treated with 0.01% DMSO, 1uM Tamoxifen (TAM), 100pg E2 or 1uM 
fulvestrant.  
 
Adenoviral Transduction 
The adenoviruses AdEmpty (EV), AdMnSOD (SOD), and AdCatalase (CAT) were 
manufactured at ViraQuest, Inc. (North Liberty, IA, USA) by inserting either Ad5 
E1/partial E3-deleted replication-deficient adenoviral vector only (EV) or the vector 
containing MnSOD (SOD) or Catalase (CAT) gene in the E1 region of the vector.  
 
LCC2 cells were seeded in 100-mm dishes at a density of 1 × 106 cells/dish in the 
medium containing charcoal stripped FBS for 24hrs. The medium was then aspirated and 
replaced with 5 ml of serum-free medium containing 50pfu of SOD, CAT or EV 
adenovirus. After 2 hours of incubation, 10% of charcoal stripped serum was added to the 
medium making it 5% charcoal stripped medium. Medium was changed after 24 hours of 
adenoviral exposure and treatment(s) were added to pre-designated plates and incubated 
for another 48 hours.  
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Ebselen Pre-treatment 
1x106 LCC2 cells were seeded per 100mm dish in medium with 5% Charcoal stripped 
serum. 21 hours post seeding 20μM of Ebselen was added to the culture and incubated 
for 3hours.  Desired treatments were then added to the culture and incubated for 48 hours. 
 
BrdU Incorporation Assay 
For BrdU incorporation, LCC2 cells were seeded in 96-well plates at a density of 
2500/well and incubated in 5% CO2 incubator at 37oC. 24 hours after seeding, cells were 
either infected with EV, CAT or SOD at a multiplicity of infection (m.o.i) of 50pfu/cell 
as described above or pre-treated with 20 μM of Ebselen. After exposure to antioxidants 
cells were then stimulated with either 0.01% DMSO, E2 (100pg), TAM (1uM) or E2 + 
TAM for 48hours. Following the above treatment, BrdU incorporation assay was carried 
out using Cell Proliferation ELISA, BrdU labeling Kit (Roche Molecular Biochemical) in 
accordance with manufacturer’s recommendation. Colorimetric changes were acquired at 
370 nm with a Tecan Genios microplate reader. 
 
2′, 7′-dichlorofluorescin diacetate (DCFH-DA)  
To carry out the DCFH-DA Assay, 10,000/well of LCC2 cells were seeded in a 96-well 
plate and cultured in 10% growth medium for 24 hours. After 24 hours growth medium 
was aspirated and replaced with serum free medium for another 24 hours after which the 
starvation media was aspirated and replaced with 100uL/well of HBSS containing 10 μM 
DCFDA pre-diluted with Pluronic F-127 and incubated at 37oC for 20 mins. At the end of 
the incubation, DCFH-DA solution was gently aspirated and pre-designated wells were 
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then stimulated with 100ul of HBSS containing either 0.01% DMSO (vehicle control), E2 
(100pg), TAM (1uM) or E2 + TAM. Cells were further incubated for 5mins after which 
fluorescence readings were taken using 485 nm and 535 nm as excitation and emission 
filters, at intervals of 5 mins. Optical density readings were obtained using a Tecan 
Genios microplate reader. 
 
 Western blot  
1 x 106 LCC2 cells per 100mm dish were initially exposed to antioxidants as described 
above and then stimulated with either 0.01% DMSO, 1μM TAM, or 1μM fulvestrant for 
48hours. Post treatment, cells were harvested and lysed in radioimmunoprecipitation 
assay (RIPA) buffer [25 mM Tris HCl (pH 7.4), 25 mM NaCl, 1 mM sodium 
orthovanadate,10 mM sodium  pyrophosphate, 10 mM NaF, 0.5 mM EGTA, 1.0% Triton 
X-100, 1 mM PMSF, and 10 mM okadaic acid] for 15 min on ice. Samples were then 
briefly sonicated and centrifuged at 10,000 rpm for 10 min at 4°C. The total protein 
concentration of the resulting supernatant was determined by Pierce BCA quantification 
kit. Equal amount of protein extracts (50 μg) were separated by SDS-PAGE, transferred 
to a polyvinylidene difluoride membrane (PVDF), blocked in 1% BSA and fat free milk 
solution containing 50 mM NAF for 1hour and blotted with antibodies. Labeled proteins 
are visualized with an ECL system (Amersham Biosciences). Band intensity was 
determined using densitometric analysis (NIH ImageJ software). The level of p27 was 
expressed as its ratio to β-actin. 
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For chronic exposure, after exposing cells to antioxidants cells were stimulated with 
either DMSO, TAM, or fulvestrant for 21 days after which the cells were harvested for 
lysate preparation and Immunoblotting as described above. 
 
Co-immunoprecipitation  
For co-immunopreipitation to determine Cyclin E complexes, the Exactacruz protocol 
was followed according to the manufacturer’s recommendation. Briefly, after stimulation, 
lysate was prepared using ice-cold Nonidet P-40 lysis buffer (0.1% Nonidet P-40, 50 mM 
Tris [pH 7.5], 150 mM NaCl, 1 mM phenylmethylsulfonyl fluoride, and 0.02 mg each of 
aprotinin, leupeptin, and pepstatin per ml). The lysate was then sonicated briefly and 
centrifuged at 10,000 rpm for 10 mins. Supernatant was saved and then pre-cleared using 
30 μl of Exactacruz pre-clearing matrix for 30minutes at 4oC while rotating. Matrix was 
pelleted by microcentrifugation at maximum speed for 30 seconds at 4°C and the 
supernatant (cell lysate) was transferred to a new micro centrifuge tube and BCA assay 
performed. 
 
IP antibody-IP matrix complex was formed by adding 2 μg of Cyclin E antibody to be 
immunoprecipitated to 40 μl of suspended IP matrix and 500 μl PBS and incubating at 4° 
C on a rotator overnight. After overnight incubation, matrix was pelleted, supernatant 
discarded and pelleted matrix was washed two times with 500 µl of PBS, each time while 
repeating the above centrifugation and aspiration steps. After the second wash and micro-
centrifugation, 300 μg of pre-cleared lysate was added to the IP antibody-IP matrix 
complex, and incubated overnight at 4° C after which samples were microcentrifuged at 
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maximum speed for 30 seconds at 4° C to pellet IP matrix and the pelleted matrix washed 
2-4 times with NP40 lysis buffer and pelleted. After the final wash, 40 µl of 2X reducing 
electrophoresis buffer was added to the pellet, boiled for 3 mins, quick-spinned and equal 
volumes loaded onto gel, resolved, transferred, and blotted with Cyclin E, Cdk2, and p27 
antibodies. Antibody alone, and whole cell lysate controls were run alongside 
immunoprecipitates. The same was done for CDK2 and p27. Western blot anti-body was 
probed using the appropriate HRP conjugated ExactaCruz reagent.  
 
Soft Agar Colony Formation Assay.  
To assess the effect of antioxidants on anchorage-independent cell growth, a soft agar 
colony formation assay using either plain or antioxidant pretreated (Ebselen, Catalase or 
MnSOD) LCC2 cells was performed. LCC2 cells (1000/well) were suspended in 0.2ml of  
charcoal stripped culture  medium containing 0.25% agar and appropriate treatment 
(0.01% DMSO or 1μM Tamoxifen or fulvestrant) and poured over a pre-hardened feeder  
layer of agarose comprising 0.2 ml of the charcoal stripped medium, containing 0.5% 
agar, in a 48 well plate. Cells were fed every 4 days and allowed to incubate for 30 days. 
After 14 days of incubation at 37°C in a humidified CO2 incubator, colonies were 
counted excluding any colonies with a diameter ≤ 60 μ meter. 
 
P27 protein stability 
To determine the effect of antioxidants on p27 stability, 1 x 106 LCC2 cells were seeded 
in 100 mm plates in medium with charcoal stripped FBS for 24hours and then some cells 
were exposed to either Ebselen or 50 pfu of CAT, SOD or EV. After 24 hours media was 
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replaced with fresh medium with charcoal stripped FBS alone for 40 hours.  After which 
50 μM of cycloheximide was added to media for the indicated period spanning the next 8 
hours. Cells were lysed in RIPA buffer for 60 min at 4°C. Samples were then centrifuged 
at 10,000g for 10 min at 4°C. The total protein concentration of the resulting supernatant 
was determined by BCA quantification. Equal amount of protein extracts (50 μg) were 
separated by SDS-PAGE, transferred to a PVDF membrane, blocked in 1% BSA and fat 
free milk solution containing 50 mM NAF for 1 hour and blotted with antibodies. 
Labeled proteins are visualized with an ECL system (Amersham Biosciences). Band 
intensity was determined using densitometric analysis (NIH ImageJ software). The level 
of p27kip was expressed as its ratio to β-actin. 
 
Results 
Antioxidants mitigate ROS formation in TAM resistant LCC2 cells 
To determine the effect of antioxidants on TAM-induced ROS in LCC2 cells, a DCFH-
DA assay was performed using cells with or without antioxidants. Data reveals that 
LCC2 cells generate ROS when exposed to TAM and E2 respectively and the ROS 
generated was significantly inhibited by the co-treatment of TAM with E2 (Figs. 1A). 
This observation implies that while individual treatment of LCC2 cells with E2 and TAM 
are pro-oxidant, TAM possesses an anti-oxidant effect in the presence of E2. Co-
treatments of cells with either TAM or E2 and ROS modulators (biological or chemical) 
also inhibited TAM-induced ROS (Figs. 1B, C). 
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Antioxidants inhibits BrdU incorporation in TAM resistant cells 
A BrdU incorporation assay was carried out to determine the effect of antioxidants on 
ROS induced DNA synthesis in LCC2 cells. Experimental outcomes show that E2 and 
TAM-induced cell proliferation in LCC2 cells is significantly inhibited by the co-
treatment of TAM with E2 (Fig. 2A) and by co-treatment of TAM or E2 with Biological 
(CAT or SOD) or chemical (Ebselen) ROS modulators (Figs. 2B, C). The ability of ROS 
modulators to inhibit TAM or E2 induced DNA synthesis points to the pro-oxidant effect 
of TAM or E2 on LCC2 cells and the inherent capacity of this pro-oxidant environment 
to promote cell proliferation. 
  
Antioxidants mitigate anchorage independent growth in TAM resistant LCC2 cells.  
To determine the effect of antioxidants on anchorage-independent growth in TAM 
resistant cells, a colony assay was performed using LCC2 cells. Anchorage independent 
growth was significantly inhibited by fulvestrant but not by TAM or DMSO (Fig.3A). 
fulvestrant was included in this experiment as a positive control because LCC2 cells are 
sensitive to it. Ebselen pretreatment or the over expression of CAT or SOD in TAM 
resistant LCC2 cells significantly inhibited anchorage independent growth compared to 
EV infected or uninfected cells (Figs. 3B, C). This result further substantiates the pro-
oxidant, growth inducing effect of TAM. 
  
Antioxidants increased p27 expression in TAM resistant cells 
Western blotting was carried out to determine the effect of antioxidants on TAM resistant 
cells. Fig. 4A reveals that the treatment of LCC2 cells with fulvestrant significantly 
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increased p27 expression compared to TAM. Ebselen pretreatment or the over expression 
of CAT or SOD in LCC2 cells also resulted in a significant increase in p27 expression 
when treated with TAM compared to EV infected cells and uninfected cells (Fig.4B, C). 
This is similar to the effect observed following exposure to fulvestrant in Fig.4A. It may 
thus be inferred that the TAM induced pro-oxidant environment may promote LCC2 cell 
proliferation by decreasing p27 expression. 
    
Antioxidants decreased p27 phosphorylation in TAM resistant cells 
Western blotting was also carried out to determine the effect of antioxidants on p27 
phosphorylation. Panel I. Results obtained from this experiment show that treatment of 
uninfected LCC2 cells with fulvestrant resulted in significantly reduced phosphorylation 
of p27 on Threonine 157(T157) relative to TAM treated cells which showed a 
phosphorylation level that was ≥ T157 phosphorylation in cells exposed to DMSO 
control (Fig.5A). Over expression of CAT or SOD or Ebselen pretreatment in LCC2 cells 
leads to a significant decrease in T157 phosphorylation when treated with TAM 
compared to either EV infected control or uninfected cells. (Figs.5B, C). Once again the 
cells exposed to ROS modulators acted like those exposed to fulvestrant by showing a 
decrease in p27 phosphorylation on T157 unlike the unexposed cells which showed an 
increase in T157 phosphorylation. It is noteworthy that phosphorylation of p27 on T157 
results in increased cytoplasmic sequestration of p27 and vice versa.  
 
Panel II. In Fig.5A Experimental outcome reveals a significant reduction of p27 
phosphorylation on Threonine 187 (T187) in LCC2 cells exposed to fulvestrant compared 
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to TAM. (B) LCC2 cells over expressing CAT or SOD or pretreated with Ebselen also 
shows a significant reduction in the level of p27 phosphorylation on T187 when treated 
with TAM compared to either EV control or uninfected cells. 
A result similar to the one obtained for T157. 
 
Prolonged exposure of LCC2 cells to antioxidants and TAM treatment increased 
p27 expression 
Immunoblotting was carried out to determine the effect of chronic antioxidant and TAM 
exposure on p27 expression. Results obtained show that prolonged (21 days) exposure of 
LCC2 cells to fulvestrant significantly increased p27 expression compared to TAM (Fig. 
6A). Over expression of CAT or SOD in LCC2 cells also resulted in a significant 
increase in p27 expression when treated with TAM compared to EV infected cells and 
uninfected cells (Fig.6B). This shows that chronic exposure to antioxidants and TAM 
have the same outcome as short term (48hrs) exposure.  
 
Prolonged exposure of LCC2 cells to antioxidants and TAM treatment reduced p27 
phosphorylation 
The following are results from Immunoblotting to determine the effect of antioxidants on 
p27 phosphorylation. Panel I. Chronic treatment of uninfected LCC2 cells with 
fulvestrant resulted in a significant reduction in the phosphorylation of p27 on Threonine 
157(T157) compared to TAM treated cells which showed an increase in the level of p27 
phosphorylation on T157(Fig.7A). Treatment of LCC2 cells over expressing CAT or 
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SOD also resulted in a reduction in phosphorylation when compared to either EV control 
or uninfected cells exposed TAM (Fig.7B).  
 
Panel II. Fig.8A shows that chronic exposure of LCC2 cells to fulvestrant resulted in a 
significant reduction in the level of p27 phosphorylation on Threonine 187 (T187) 
compared to TAM. LCC2 cells over expressing CAT or SOD upon treatment with TAM 
showed a significant reduction in phosphorylation when compared to either EV control or 
uninfected cells exposed to TAM. 
 
Antioxidants increased p27 binding to CylinE and CDK2 in TAM resistant cells 
To determine the effect of Antioxidants on p27 binding to CDK2 and or CyclinE a co- 
immunoprecipitation was performed. Treatment of LCC2 cells with fulvestrant resulted 
in an increase in p27 binding to CDK2 and CyclinE compared to TAM treatment (Fig. 
8A). Ebselen pretreatment or the Over expression of CAT or SOD in LCC2 also resulted 
in increased binding of p27 to CDK2 and CyclinE when treated with TAM compared to 
either EV infected controls or uninfected cells exposed to TAM (Fig.8B, C). 
 
Antioxidants increased CDK2 binding to P27 and CyclinE in TAM resistant cells To 
determine the effect of Antioxidants on p27 binding to CDK2 and or CyclinE a co- 
immunoprecipitation was performed. Treatment of LCC2 cells with fulvestrant resulted 
in an increase in CDK2 binding to p27 and CyclinE compared to TAM treatment (Fig. 
9A). Ebselen pretreatment or the Over expression of CAT or SOD in LCC2 also resulted 
 96 
in increased binding of CDK2 to p27 and CyclinE when treated with TAM compared to 
either EV infected controls or uninfected cells exposed to TAM (Fig.9B, C). 
  
Antioxidant Increased CylinE binding to CDK2 and p27 in TAM resistant cells 
To determine the effect of antioxidants on CyclinE binding to CDK2 and or p27 a co- 
immunoprecipitation was performed. In (Fig. 10A), treatment of LCC2 cells with 
fulvestrant resulted in an increase in CyclinE binding to CDK2 and p27 compared to 
TAM while data from (Fig.10B, C) also showed increased CyclinE binding to CDK2 and 
p27 in LCC2 cells over expressing CAT or SOD compared to either EV infected cells or 
uninfected cells exposed to TAM.  
  
P27 expression is less in LCC2 cells compared to MCF7 when synchronized  
Pursuant to the finding in Figures 4 and 5 Immunoblotting was performed to compare the 
levels of p27 in TAM resistant LCC2 cells to its parent MCF7 cells. Results obtained 
showed the level of p27 expression in LCC2 to be about 40% less than that in MCF7 
cells of equal protein concentration, exposed to the same experimental conditions. 
 
Antioxidants Increased p27 stability in TAM resistant cells 
To determine p27 stability a stability assay was performed using cycloheximide. LCC2 
cells not pre-exposed to antioxidants had a shorter half life (2.42hours) compared to CAT 
or SOD over expressing cells. 
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Discussion 
In this study, we hypothesized that, (i) In addition to its known action at the ER, TAM 
also prevents estrogen-mediated progression of cell cycle by counteracting estrogen-
induced ROS signaling, and (ii) As a result of chronic oxidative stress, the conversion of 
estrogen-sensitive breast tumors to a Tamoxifen-resistant phenotype is associated with a 
progressive shift towards a pro-oxidant environment. We therefore propose that an 
increase in ROS levels promotes the loss of p27 inhibitory function through the 
inactivation of protein tyrosine phosphates (PTPs) and a consequent change in p27 
phosphorylation. 
 
TAM, a known selective estrogen receptor modulator (SERM), has been widely shown to 
possess either pro- or antioxidant properties 7-13. Our results show that TAM possesses 
the capacity to act like both an oxidant and an antioxidant. Exposure of LCC2 cells to 
TAM or E2 induced the formation of reactive oxidants (Fig.1A). These reactive oxidants 
were then inhibited by the co-treatment of E2 with TAM, much like the ROS inhibition 
observed in cells pre-treated with antioxidants (Figs.1B & C). We further demonstrated 
that E2 and TAM induced ROS in LCC2 cells were capable of inducing cell proliferation 
which was then inhibited by pre-exposure of the cells to biological or chemical 
antioxidants or the co-treatment of TAM with E2 (see Figs.2 & 3). These findings make a 
case for the dual role of TAM as both a pro- and an antioxidant. Based on these results, it 
appears that the antioxidant effect of TAM is observed in the presence of E2.  
Exposure of TAM resistant LCC2 cells to TAM resulted in a decrease in p27 expression 
in contrast to the increase in p27 expression observed when the same cells were treated 
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with fulvestrant (see Fig.4A). Fulvestrant is an anti-estrogen to which LCC2 cells are 
known to be sensitive. We also observed that the exposure of these cells to TAM 
increased p27 phosphorylation on T157 and T187 while exposure to fulvestrant appeared 
to have the opposite effect (Fig5. Panels 1& IIA). 
 
Conversely, following the antioxidant pre-treatment/over expression, a fulvestrant-like 
effect i.e., an increase in p27 expression (see Figs. 4B &C) and a decrease in p27 
phosphorylation on T157 and T187 was observed in TAM treated cells compared to cells 
which were not pre-exposed to antioxidants (Figs. 5 Panels I & II B & C). It can thus be 
inferred that the over expression of antioxidant in LCC2 cells leads to an increase in p27 
expression and a decrease in its phosphorylation on T157 and T187. This is in line with 
other previous studies 40 - 42, which showed that treatment with anti-estrogen drugs like 
TAM or fulvestrant caused cell cycle arrest, with up-regulation of p21 and p27 levels, an 
increase in their binding to Cyclin E–Cdk2, and kinase inhibition 40. Additionally, results 
from our comparison of p27 expression between Tamoxifen sensitive parental MCF7 and 
Tamoxifen resistant LCC2 cells showed a 40% decrease in p27 expression in LCC2 cells 
compared to MCF7 (Fig.11). This implies that TAM resistance could be associated with a 
decrease in p27 expression rather than the loss p27 function in which case, an increase in 
p27 expression following antioxidant pre-treatment is a significant finding.  
 
Though the observed experimental outcomes imitate the effect of fulvestrant on LCC2 
cells, we cannot yet interpret this to either denote an increase in TAM sensitivity or the 
growth inhibitory function of p27. This is because previous studies have indicated that 
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p27 potentially has dual role(s) in tumor – suppression and promotion 43-46 depending on 
its subcellular redistribution and its binding to the Cyclin-Cdk complex. The binding of 
p27 to the Cyclin E/Cdk2 complex in the nucleus promotes its function as a CKI while 
cytoplasmic sequestration takes it away from its nuclear Cyclin/Cdk target to the growth 
promoting interaction with Cyclin D/Cdk4/6 complex 47.  
 
In line with previous studies 40, we also found an increase in the binding of Cyclin E–
Cdk2 and p27 in TAM treated cells over expressing antioxidant (CAT and SOD) 
compared to control cells not exposed to antioxidants (see Figs. 8, 9 & 10). In the context 
of our initial finding of increased p27 expression and decreased phosphorylation, these 
results of increased binding of p27 to Cyclin E–Cdk2 and increased p27 stability in cells 
over expressing antioxidants (Fig. 12), are highly suggestive of an increase in the TAM 
sensitivity, most likely due to p27 inhibitory function in antioxidant over expressing 
LCC2 cells. 
 
In summary, we demonstrate that TAM has the capacity to induce ROS formation and act 
as an antioxidant in the presence of E2. Following prolonged exposure to TAM and an 
increasingly pro-oxidant environment, the oxidants formed are able to promote cell 
proliferation. This could be by decreasing p27 expression and regulation of its activity by 
post-translational modification involving an increase in p27 phosphorylation on T157 and 
T187. This is accompanied by a resultant cytoplasmic sequestration, decreased binding to 
Cyclin E/Cdk2 complex and loss of p27 stability resulting in the loss of sensitivity to 
TAM. Clearly, these events are oxidant driven, therefore they can be reversed by 
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antioxidant over expression or pre-treatment, with a resultant growth inhibitory effect and 
increased TAM sensitivity.  
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Figures and Legend 
Fig 1-LCC2.  
 
Antioxidants mitigate ROS formation in TAM resistant LCC2 cells. To determine the 
effect of antioxidants on TAM induced ROS in LCC2 cells, 1 x104cells/well were seeded 
in a 96-well plate overnight and serum starved for 24 hrs. Post-starvation 100 μL/well of 
HBSS containing 10 μM DCFH-DA pre-diluted with Pluronic F-127 was added to each 
well and incubated at 37oC for 20 mins.  DCFH-DA solution was then aspirated and 
replaced with 100 μL of HBSS containing the desired treatments. Cells were further 
incubated for 5 mins and fluorescence readings were taken using 485 nm and 535 nm as 
excitation and emission filters, at intervals of 5mins. A) LCC2 cells treated with TAM, 
E2 or TAM/E2; B) TAM resistant cells over expressing Catalase (CAT) and MnSOD 
(SOD) were treated with TAM, E2 or TAM/E2; C) LCC2 cells co-treated with Ebselen 
and TAM, E2 or TAM/E2. Assay was performed 3x and data is expressed as mean 
percentage change from control +/- SE, (p 0.05).  (*) denotes significance when treatment 
is compared to DMSO control, (**) indicates significance when compared to EV/DMSO 
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control while (***) indicates significance when treatment is compared to DMSO and 
each individual treatment.  
 
Fig 2-LCC2 
 
Antioxidants inhibit BrdU incorporation in TAM resistant cells. To determine the 
effect of antioxidants on ROS induced DNA synthesis in LCC2 cells, 2.5 x 103 cells/well 
were seeded in a 96-well plate overnight and exposed to chemical or biological 
antioxidants as described in methods. After exposure to antioxidants, cells were then 
stimulated with E2, TAM or fulvestrant for 46 hrs and pulsed labeled with BrdU for 2 
hrs. BrdU assay was then carried out as recommended by manufacturer. Colorimetric 
changes were acquired at 370 nm with a Tecan Genios microplate reader at 5 mins 
interval. A) LCC2 cells treated with TAM, E2 or TAM/E2; B) TAM resistant cells over 
expressing CAT and SOD and treated with TAM, E2 or TAM/E2; C) LCC2 cells co-
treated with Ebselen and TAM, E2 or TAM/E2. Assay was performed 3x and data is 
expressed as mean percentage change from control +/- SE, (p 0.05). (*) denotes 
significance when treatment is compared to DMSO control, (**) indicates significance 
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when compared to EV/DMSO control while (***) indicates significance when treatment 
is compared to DMSO and each individual treatment. 
 
Fig 3-LCC2 
 
Antioxidants mitigate anchorage independent growth in TAM resistant LCC2 cells. 
To determine the effect of antioxidants on anchorage-independent growth in TAM 
resistant cells, LCC2 cells were incubated on soft agar with or without antioxidants 
exposure for 21 days and colonies ≥60 microns in diameter were enumerated. A) 
Anchorage independent growth of TAM resistant cells; B) LCC2 cells over expressing 
Catalase (CAT) or MnSOD (SOD); C) LCC2 cells pretreated with chemical antioxidant.  
Assay performed 3x and data is expressed as mean percentage change from control +/- 
SE, (p 0.05).  (*) denote significance when treatment is compared to DMSO control 
while (**) indicates significance when compared to EV/DMSO control. 
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Fig 4-LCC2 
 
Antioxidants Increased p27 expression in TAM Resistant cells. LCC2 cells were 
exposed to antioxidants as described in methods and treated with TAM and fulvestrant 
respectively. After 48 hrs incubations, cells were harvested with lysis buffer and 50 ug 
whole cell lysate (WCL) were fractionated on 12% SDS-PAGE gel. Immunoblots were 
probed with p27 or β actin antibodies respectively. A) LCC2 cells treated with TAM or 
fulvestrant, B) LCC2 cells over expressing CAT or SOD, then treated with TAM and 
Fulv, C) LCC2 cells co-treated with chemical antioxidant and TAM or Fulv. Assay was 
performed 3x. P27 protein level was determined by densitometric analysis and expressed 
as the percentage mean of its ratio with β actin relative to control +/- SE, (p 0.05).  (*) 
denotes significance when treatment is compared to DMSO control while (**) indicates 
significance when compared to EV/DMSO control. 
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Fig 5-LCC2 
 
Antioxidants decreased p27 phosphorylation in TAM Resistant cells. (Panel I) A) 
LCC2 cells treated with TAM or Fulv and probed with p27 or p27 phosphorylated on 
Threonine 157 (T157); B) LCC2 cells over expressing CAT or SOD were treated with 
TAM and Fulv, then probed with p27 or T157; C) LCC2 cells co-treated with chemical 
antioxidant and TAM or Fulv,  then probed with p27 or T157. (Panel 2) A) LCC2 cells 
treated with TAM or Fulv and probed with p27 or p27 phosphorylated on Threonine 187 
(T187); B) LCC2 cells over expressing CAT or SOD were treated with TAM and Fulv, 
then probed with p27 or T187; C) LCC2 cells co-treated with chemical antioxidant and 
TAM or Fulv, then probed with p27 or T187. Assay was performed 3x. Phosphorylated 
p27 levels were determined by densitometric analysis and expressed as the percentage 
mean of their ratios to the ratio of p27 with β actin relative to control +/- SE, (p 0.05).  (*) 
is denotes significance when compared to DMSO control while (**) indicates 
significance when compared to EV/DMSO control. 
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Fig. 6-LCC2 
 
Prolonged antioxidant treatments increased p27 expression in LCC2 cells. LCC2 
cells over expressing CAT or SOD were exposed to either TAM or Fulv for 21 days. A) 
Uninfected cells were treated with TAM or Fulv and probed for p27 and actin; B) CAT or 
SOD infected cells treated with TAM or Fulv and probed for p27 and β actin. Assay was 
performed 3x. P27 protein level was determined by densitometric analysis and expressed 
as the percentage mean of its ratio with β actin relative to control +/- SE, (p 0.05).  (*) 
denotes significance when treatment is compared to DMSO control while (**) indicates 
significance when compared to EV/DMSO control. 
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Fig 7-LCC2 
 
Prolonged exposure of LCC2 cells to Antioxidants decreased p27 phosphorylation in 
LCC2. (Panel I) A) LCC2 cells treated with TAM or Fulv for 21 days and probed with 
p27 or T157; B) LCC2 cells over expressing CAT or SOD were treated with TAM and 
Fulv for 21 days, and then probed with p27 or T157. (Panel II) A) LCC2 cells treated 
with TAM or Fulv for 21 days and probed with p27 or T187; B) LCC2 cells over 
expressing CAT or SOD were treated with TAM and Fulv for 21 days, and then probed 
with p27 or T187. Assay was performed 3x. Phosphorylated p27 levels were determined 
by densitometric analysis and expressed as the percentage mean of their ratios to the ratio 
of p27 with β actin relative to control +/- SE, (p 0.05).  (*) denotes significance when 
compared to DMSO control while (**) indicates significance when compared to 
EV/DMSO control. 
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Fig 8-LCC2. 
 
  
Antioxidant Increased p27 binding to CylinE and CDK2 in TAM resistant cells. 
LCC2 were exposed to antioxidants as described in methods and treated with TAM and 
fulvestrant respectively. After 48 hrs incubations, cells were harvested with lysis buffer 
and 350 ug WCL was immunoprecipitated (IP) with p27 antibody using Exactacruz kit as 
recommended. Eluent was fractionated on 12% SDS-PAGE gel. Immunoblots were 
probed with p27, CDK2 or CyclinE antibodies respectively. A) LCC2 cells treated with 
TAM or Fulv, B) LCC2 cells over expressing CAT or SOD, then treated with TAM and 
Fulv, C) LCC2 cells co-treated with chemical antioxidant and TAM or Fulv. 
 
 
 
 
 
 
 
 112 
Fig 9- LCC2 
 
 
Antioxidants Increased CDK2 binding to CylinE and p27 in TAM resistant cells. 
LCC2 were exposed to antioxidants as described in methods and treated with TAM and 
fulvestrant respectively. After 48 hrs incubations, cells were harvested with lysis buffer 
and 350 ug WCL was immunoprecipitated (IP) with CDK2 antibody using Exactacruz kit 
as recommended. Eluent was fractionated on 12% SDS-PAGE gel. Immunoblot were 
probed with, CDK2, p27 or CyclinE antibodies. A) LCC2 cells treated with TAM or 
Fulv, B) LCC2 cells over expressing CAT or SOD, then treated with TAM and Fulv, C) 
LCC2 cells co-treated with chemical antioxidant and TAM or Fulv.  
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Fig10-LCC2 
 
 
Antioxidant Increased CylinE binding to CDK2 and p27 in TAM resistant cells. 
LCC2 were exposed to antioxidants as described in methods and treated with TAM and 
fulvestrant respectively. After 48 hrs incubations, cells were harvested with lysis buffer 
and 350 ug WCL was immunoprecipitated (IP) with CDK2 antibody using Exactacruz kit 
as recommended. Eluent was fractionated on 12% SDS-PAGE gel. Immunoblots were 
probed with, CyclinE, p27 or CDK2, antibodies respectively. A) LCC2 cells treated with 
TAM or Fulv, B) LCC2 cells over expressing CAT or SOD, then treated with TAM and 
Fulv, C) LCC2 cells co-treated with chemical antioxidant and TAM or Fulv. 
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Fig11-LCC2 
 
P27 expression is less in LCC2 cells compared to MCF7. 1million LCC2 and MCF7 
cells were seed and serum starved for 48 hours after which cells were harvested with lysis 
buffer and 50 ug whole cell lysate (WCL) were fractionated on 12% SDS-PAGE gel. 
Immunoblot were probed with p27 or beta actin antibodies respectively. Figure shows 
p27 and Actin expression in LCC2 and MCF7 cells. Assay was performed 3x. P27 
protein level was determined by densitometric analysis and expressed as the percentage 
mean of its ratio with β actin relative to control +/- SE, (p 0.05 (*) is indicates 
significance when p27 expression in LCC2 cells is compared to that of MCF7 cells. 
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Fig12-LCC2 
 
 
Antioxidants increased p27 stability. Uninfected LCC2 cells (A) and LCC2 cells over 
expressing CAT(B), SOD(C) or EV(D) were treated with 50uM cycloheximide (CHX) 
for the time periods indicated, and p27 protein levels were determined by 
immunoblotting and densitometry with β actin as internal control.  
 
IV ESTROGEN INDUCED ROS MEDIATES IN VITRO CELL 
PROLIFERATION AND GROWTH THROUGH PTEN OXIDATION AND AKT-
NRF-1 PHOSPHORYLATION 
 
Abstract 
Tamoxifen resistance is still a significant problem in the treatment of estrogen receptor 
positive breast cancer.  Due to de novo resistance, only about 70% of breast cancer 
patients will initially respond to tamoxifen treatment. About 40% of patients who were 
initially responsive to the drug and majority of the patients with metastatic breast disease 
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will develop an acquired resistance to the drug over time. Although there has been an 
improvement in our understanding of the subject, the molecular mechanism(s) that result 
in the evolution of tamoxifen resistant breast cancer is still unclear. In this study we 
explored the role of reactive oxygen species (ROS) in the advancement of breast cancer 
from a tamoxifen-sensitive to a tamoxifen-resistant phenotype. ROS are products of 
cellular metabolism and an excessive and/or sustained increase in their production has 
been implicated in the pathogenesis of cancer. Furthermore, ROS induces oxidative stress 
which has been shown to initiate various cellular responses including alteration of 
intracellular redox state and the oxidative modification of certain signaling proteins 
resulting in the post translational modification of their downstream targets. Interestingly, 
tamoxifen like estrogen, has been shown to induce ROS formation, making it probable 
that tamoxifen induced ROS generated as a result of prolong tamoxifen treatment of 
breast cancer patients may play a critical role in the development of its resistance. Using 
MCF7 breast cancer cells and standard laboratory techniques, we explored the role of 
ROS and redox signaling in development of tamoxifen resistance in breast cancer cells. 
We were interested in finding out how and if ROS, through the oxidation of Phosphatase 
and tensin homolog (PTEN) induces the phosphorylation and activation of nuclear 
respiratory factor 1(NRF-1) resulting in its binding to the promoter region of certain cell 
cycle genes, thereby promoting cell proliferation and a transformation of the cells to a 
resistant phenotype. We also wanted to find out if this process can be reversed by pre-
exposing the cells to biological or chemical antioxidants. Our finding was that, 
tamoxifen-induced ROS oxidizes PTEN resulting to the hyper-stimulation of the 
Akt/PI3K pathway and a consequent NRF-1phophorylation/activation. Activated NRF-1 
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then binds to the promoter region of some cell cycle genes inducing cell proliferation. We 
also found that pre-treating the cell with anti-oxidants restored sensitivity to tamoxifen.  
 
Introduction 
PTEN (phosphatase and tensin homologue deleted from chromosome 10) is a redox 
sensitive dual specificity phosphatase 1. It is a known tumor suppressor because of its 
ability to regulate the cell cycle either by preventing cells from dividing too fast or 
dividing in an uncontrolled manner 2 such as that seen in cancer cells. The protein which 
is a negative-regulator of the phosphatidylinositol 3-Kinase (PI3K)/Akt pathway acts by 
dephosphorylating  phosphatidyl-inositol3,4,5-trisphosphate (PI(3,4,5)P3) at the 3’ 
position of the inositol ring, thereby counteracting the effect of PI3K and inactivating this 
key player in the survival pathway 3. 
 
The tumor suppressor aspect of PTEN function is pertinent in the context of human 
disease since a number of studies have found PTEN deficiency, which could arise either 
by polymorphic mutation or gene deletion, to be a cause of cancer 4, 5. Indeed one of the 
reasons for the activation of Akt signaling in cancers is the mutation or inactivation of 
PTEN 6. However, PTEN inactivation and the resulting PI3K/Akt pathway hyper-
activation could occur through mechanisms other than those that target the integrity of 
the gene 7.  
 
Alternate mechanisms of the down regulation of PTEN activity by posttranslational 
modifications such as phosphorylation and oxidation, though not directly implicated in 
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cancer, have been documented 8-11. Furthermore, reactive oxygen species (ROS) have 
been shown to oxidize PTEN at its active site ensuing in the formation of a disulphide 
bond and a subsequent PTEN inactivation. Several studies have demonstrated the ability 
of reactive oxygen species to reversibly oxidize PTEN and other dual specificity 
phosphatases, leading to their temporary inactivation 12 -13. Indeed a number of studies 
have looked into the temporary inactivation of PTEN by ROS and its effect on 
downstream molecules like Akt and its substrates. For example Connor et al and others 
have shown that PTEN oxidation enables PtdIns(3,4,5)P3 to directly activate Akt, which 
in turn activates p70 S6 kinase and inhibits the Akt substrate,  glycogen synthase kinase-3 
thereby  regulating cellular metabolism and the cell cycle 13,14. 
 
A less well known Akt substrate is NFF1 (nuclear respiratory factor-1/α-palindrome-
binding protein) 15 which is a redox sensitive transcription factor 16 that has been shown 
to regulate metabolism and cell proliferation 17-20. A study by Piatandosi and Suliman 
(2006), has demonstrated how stimulation of PI3K by exogenous oxidants activate Akt 
and promotes NRF1 phosphorylation and nuclear translocation 15. Additionally, it has 
been shown that exposure of breast cancer cells to estrogen (E2) induces cell growth 21 
and an increase in NRF1 expression 22. Since estrogen has been shown to promote ROS 
formation 23, we considered it pertinent to examine a hitherto unexplored possibility that 
E2-induced ROS could result in PTEN inactivation, a consequent increase in NRF1 
expression and phosphorylation and an effect on the cell cycle. In the event of this 
concept being cogent, we also wanted to determine the effect of antioxidants on our 
proposed pathway.  
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In this study, we show how estrogen induced PTEN oxidation in MCF7 results in the 
hyper-activation of the PI3K/Akt signaling pathway with a consequent increase in the 
expression and phosphorylation of NRF1 and a resultant binding of NRF1 to the 
promoter region of cell cycle genes. We also show how pre-exposing MCF7 cells to 
antioxidants is able to reverse the PTEN oxidation and its downstream effects.  
 
Materials and methods  
Cell culture and Materials 
MCF7 cells were obtained from Gainsville. Cells were cultured in DMEM (Gibco) 
containing 10% fetal bovine serum, 25,000 units of penicillin (base) and 25,000 µg of 
Streptomycin at 37°C in a fully humidified atmosphere of 5% CO2 in air. For 
experiments, 70% Confluent cells were further cultured in serum free DMEM to 
minimize the effect of serum and synchronize the cells in G0.  Synchronized cells were 
always stimulated with 0.01% DMSO or 100pg E2. 
 
Antibodies to NRF1 was obtained from Rockland, PTEN was obtained from cell 
signaling while p27, AKT and PAKT ser 473 were purchased from Santa Cruz 
biotechnology. T157 Phosphorylated p27 antibody was purchased from Abcam. Beta 
Actin, 2', 7’-dichlorodihydrofluorescein diacetate (DCFH-DA), DMSO and Ebselen were 
purchased from Sigma Aldrich.  BrdU kit was purchased from ROCHE. Protein A 
Agarose was purchased from Invitrogen. The adenoviruses AdEmpty (EV), AdMnSOD 
(SOD), and AdCatalase (CAT) were manufactured at ViraQuest, Inc. (North Liberty, IA, 
USA). Primers for CyclinB1, CDC2, CDC25C, PRC1and PCNA where purchased from 
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Applied Biosystems. The Upstate kit for ChIP assay was purchased from upstate 
biotechnology. 
 
Adenoviral Transduction 
The adenoviruses AdEmpty (EV), AdMnSOD (SOD), and AdCatalase (CAT) were 
manufactured at ViraQuest, Inc. (North Liberty, IA, USA) by inserting either nothing 
(EV) or the MnSOD or  Catalase gene into the E1 region of an Ad5 E1/partial E3-deleted 
replication-deficient adenoviral vector. 
 
MCF7 cells were plated in 100-mm dishes at a density of 1 × 106 cells/dish in charcoal 
stripped medium. The following day, the medium was aspirated and replaced with 5 ml 
of serum-free medium containing 200pfu of SOD, CAT or EV adenovirus for 24hours 
after which cells were stimulated with required treatments for the desired amount of time. 
 
Ebselen Pre-treatment 
1million MCF7 cells were plated per 100mm dish in 10% serum medium. 21hours post 
seeding 20uM of Ebselen was added to the medium for 3hours after which cells were 
stimulated with the desired treatments for 24 hours. 
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BrdU Incorporation Assay 
For BrdU incorporation, MCF7 cells were seeded in 96-well plates at a density of 
2500/well and incubated in 5% CO2 incubator at 37oC. 24 hours after seeding, cells were 
either infected with AdCatalase, AdMnSOD or AdEV at a multiplicity of infection 
(m.o.i) of 290pfu/cell as described above or pre-treated with 40uM of Ebselen. After 
exposure to antioxidants cells were then stimulated with either 0.01% DMSO or E2 
(100pg) for 24hours. After stimulation, BrdU incorporation was carried out using Roche 
Bioscience (Cell Proliferation ELISA, BrdU Kit; Roche Molecular Biochemical, 
Indianapolis, IN) labeling kit in accordance with manufacturer’s recommendation. 
Colorimetric changes acquired at 370 nm with a Tecan Genios microplate reader. 
 
2′, 7′-dichlorofluorescin diacetate (DCFH-DA)  
To carry out the DCFH-DA Assay, 10,000/well of MCF7 cells were seeded in a 96-well 
plate and cultured in 10% growth medium for 24hours. After 24hours growth medium 
was aspirated and replaced with starvation medium for another 24hours after which the 
starvation media was aspirated and replaced with 100uL/well of HBSS containing 10uM 
DCFDA pre-diluted with Pluronic F-127 and incubated at 37oC for 20mins. At the end of 
the incubation, DCFH-DA solution was gently aspirated and pre-designated wells were 
then stimulated with 100ul of HBSS containing either 0.01% DMSO (vehicle control) or 
E2 (100pg). Cells were further incubated for 5mins after which fluorescence readings 
were taken using 485 nm and 535 nm as excitation and emission filters, at intervals of 
5mins. Optical density readings were obtained using a Tecan Genios microplate reader. 
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Westernblot  
1 million MCF7 cells per 100mm dish were initially exposed to antioxidants as described 
above and then stimulated with either 0.01% DMSO, or E2 30mins. Post treatment, cells 
were harvested and lysed in radioimmunoprecipitation assay buffer [25 mM Tris HCl (pH 
7.4), 25 mM NaCl, 1 mM sodium orthovanadate,10 mM sodium  pyrophosphate, 10 mM 
NaF, 0.5 mM EGTA, 1.0% Triton X-100, 1 mM PMSF, and 10 mM okadaic acid] for 15 
min on ice. Samples were then briefly sonicated and centrifuged at 10,000rpm for 10 min 
at 4°C. The total protein concentration of the resulting supernatant was determined by 
BCA quantification. Equal amount of protein extracts (50ug) were separated by SDS-
PAGE, transferred to a polyvinylidene difluoride membrane, blocked in 1% BSA and fat 
free milk solution containing 50mM NAF for 1hour and blotted with antibodies. Labeled 
proteins are visualized with an ECL system (Amersham Biosciences). Band intensity was 
determined using densitometric analysis (NIH ImageJ software). The level of protein 
level was expressed as its ratio to βactin. 
 
Soft Agar Colony Formation Assay.  
To assess the effect of antioxidants on anchorage-independent cell growth, a soft agar 
colony formation assay using either plain or Ebselen pretreated MCF7 cells was 
performed. MCF7 cells (1000/well) were suspended in 0.2ml of  charcoal stripped culture  
medium containing 0.25% agar  and appropriate treatment (0.01%DMSO, 100pg E2, 
1uM Tamoxifen, or co-treatment of TAM with E2 ) and poured over a pre-hardened 
feeder  layer of agarose comprising 0.2 ml of the charcoal stripped medium, containing 
0.5% agar, in a 48 well plate. Cells were fed every 4 days and allowed to incubate for 
 123 
30days. After 14 days of incubation at 37°C in a humidified CO2 incubator, colonies 
counted excluding any colonies with a diameter ≤ 60. 
 
Identification of Reduced and Oxidized Forms of PTEN by Immunoblot Analysis. 
After stimulation, I million/100mm dish of MCF7 cells in 1 ml of HBSS were scraped 
into 0.2 ml of ice-cold 50% trichloroacetic acid and transferred to microfuge tubes. The 
cell suspensions were sonicated briefly and then centrifuged at 2000g for 5 min. The 
supernatants were removed, and the pellets were washed with acetone and then 
solubilized in 0.2 ml of 100 mM Tris-HCl (pH 6.8) buffer containing 2% SDS and 40 
mM NEM. 5ul of the solubilized pellets were subjected to SDS-PAGE under 
nonreducing conditions, and the separated proteins were transferred electrophoretically to 
a polyvinylidene difluoride membrane. 
 
The membrane was then subjected to immunoblot analysis with either rabbit antibodies to 
PTEN or   monoclonal antibody to Beta Actin. Immune complexes were detected with 
horseradish peroxidase-conjugated secondary antibodies and enhanced 
chemiluminescence reagents (Amersham Biosciences). The intensity of PTEN bands was 
quantitated with NIH ImageJ. 
 
Chromatin Immunoprecipitation (ChIP) Assay  
This assay was carried out using the upstate protocol that came with the kit. Briefly, after 
stimulation, protein complex was cross-linked to DNA by adding formaldehyde directly 
to culture medium to a final concentration of 1% and incubate for 10 minutes at 37C. 
Cells were washed twice with ice cold PBS containing protease inhibitors scraped into 
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conical tube and Pelleted for 4 minutes at 2000 rpm at 4ºC. Cell pellet was then lysed in 
SDS Lysis buffer for 10 minutes on ice. Lysate was sonicated (5 x 15pulses) and 
centrifuged for 10 minutes at 13,000 rpm at 4°C. 150 ul of the sonicated cell pellet 
suspension was transferred to a new 1.5 ml eppendorf tube and diluted 10times in ChIP 
Dilution buffer containing protease inhibitors.  1% (~15 ul) was kept aside as 
input/starting material. 1.5 ml diluted cell pellet suspension was pre-cleared with 60 ul of 
Salmon Sperm DNA/Protein A Agarose-50% slurry for 2 hours at 4ºC with agitation. 
Agarose was pelleted by brief centrfugation (1min @ 1000rpm). The supernatant fraction 
was collected and the immunoprecipitating antibody added to the 1.5 ml supernatant 
fraction and incubate overnight at 4ºC with rotation. A non-specific antibody for 
immunoprecipitation as negative control. 40 ul of Salmon Sperm DNA/Protein A 
Agarose Slurry was added for another two hour at 4ºC with rotation to collect the 
antibody/protein complex. Agarose was then pelleted, supernatant was discarded and 
washed with different wash buffers for 3-5minutes per wash. The histone complex was 
then eluted from the antibody and  all samples including the input were reverse cross-
linked by heating at 65ºC for 6 hours. DNA was then recovered by ethanol precipitation 
and PCR analysis performed. 
 
Immunofluorescence Labeling  
Cells were seeded (1.0x104 cells/chamber) and stimulated in chamber slides as indicated 
in the legends of the figures. After treatment, cells were fixed with ice cold methanol for 
15mins, and permeabilized with 0.5% Triton X-100 for 30min. Then the cells were 
blocked with 1% normal goat sera for 1 hr after which they were probed simultaneously 
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with antibodies diluted 1: 500 for NRF1; or 1:1500 for phosphor serine. Alexa Fluor 
labeled secondary antibodies directed against primary antibodies was diluted 1:1000. The 
confocal fluorescence images were scanned on a Nikon TE2000U inverted fluorescence 
microscope equipped with a Nikon D-Eclipse C1 laser scanning confocal microscope 
system (Nikon Corp., USA). The z-series scanning were done at every 1 μm up to a z-
depth of 10 μm by using a Nikon 40 x 1.30 NA DIC H/N2 Plan Fluor oil immersion 
objective. The built-in Nikon EZ-C1 software was used for confocal image acquisition 
and analyses.  
 
Results 
Estrogen induces ROS in MCF-7. To determine whether E2 induces ROS in breast 
cancer cells, MCF-7 cells were treated with either E2 or E2 with ROS modulators as 
described in methods. Results showed that cells exposed to E2 induced ROS formations 
(Fig.1A). However, co-treatment of cells with E2 and ROS modulators (CAT or Eb) 
inhibited estrogen’s ability to induce ROS formations (Fig.1B).  
 
Estrogen induced ROS mediates in vitro proliferation and growth of MCF-7 cells. 
To ascertain whether E2 induced ROS facilitates in vitro proliferation and growth of 
breast cancer cells, MCF-7 cells were seeded for BrdU and soft agar assay as described in 
methods. Cells were subsequently treated with E2 or E2 and ROS modulators. BrdU 
incorporation, which is a marker of cells proliferation and soft agar colony formation, 
which is a hallmark of anchorage independent cancer growth, were analyzed and 
enumerated as described in methods and legends. Data indicate that E2 induced 
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proliferation of MCF-7 cells were abrogated by ROS modulators (Fig 2). Similarly, E2 
induced anchorage independent growth of breast cancer cells were abolished by ROS 
modulators (Fig 3). These findings indicate that estrogen induced proliferation and 
growth of breast cancer cells are redox dependent.  
  
Estrogen induced ROS oxidizes PTEN in MCF-7 cells. Oxidation of PTEN by ROS 
has been demonstrated to promote carcinogenesis and growth of cancer cells (PMID: 
15534200). We investigated whether E2 induced ROS also oxidizes PTEN thereby 
promoting E2 induced proliferation and growth of breast cancer cells. Western blot 
analysis indicates that while H2O2 are potent oxidizers of PTEN (Fig. 4), E2 induced 
ROS can similarly oxidize PTEN albeit to a lesser extent compared to H2O2 (Fig. 5A).  
However, when cells were co-treated with either Catalase or Ebselen, E2 induced PTEN 
oxidation were significantly reversed (Figs. 5B & C). These findings indicates that E2 
induced ROS can lead to PTEN oxidation which could alter downstream signaling 
process that favors breast cancer proliferation and growth in response to estrogens.  
    
Estrogen induced PTEN oxidation activates Akt phosphorylation in MCF7 cells. 
Western blot analysis were carried out to determine whether E2 induced PTEN oxidation 
would lead to increased Akt activation and whether ROS modulators would attenuate Akt 
activation in E2 treated breast cancer cell. Our study showed that E2 induced significant 
Akt phosphorylation compared to vehicle treated cells (Fig. 6A).  When cells were co-
treated with E2 and ROS modulators, Akt activations were significantly reduced 
(Figs.6B&C). This data indicates that E2 induced PTEN inactivation and activation of 
 127 
Akt signaling cascade in breast cancer cells are redox dependent. Activated Akt can in 
turn phosphorylate downstream substrates such as transcription factors that favor survival 
and growth of breast cancer cells.  
 
Estrogen induces NRF1 expression and phosphorylation in MCF7 cells. To 
determine the effect of Estrogen induced PTEN oxidation on downstream Akt signaling 
substrates, Immunohistochemistry assays were carried out to determine how E2 induced 
ROS affect NRF1 expression and phosphorylation.  Results show an increase in NRF1 
expression and phosphorylation in E2 treated cells compared to DMSO control (Fig.7). 
 
Estrogen induced ROS mediates NFR-1 binding to promoter regions of cell cycle 
genes in MCF7 cells. A chromatin immunoprecipitation assay was carried out to 
determine the effect of E2 on NRF1 binding as described in methods. Result obtained 
shows an E2 induced increase in NRF1 binding to the promoter region of the following 
cell cycle genes: CyclinB1, CDC2, PCNA, CDC25C and PRC1 (Fig. 8, Panels I &IIA). 
Conversely, Antioxidant pre-treatment significantly inhibited the E2 induced NRF1 
binding to the promoter region of the same genes (Fig. 8, Panels I &IIB).  
 
Estrogen induced ROS mediates transcription of Cell cycle genes. RT-PCR was 
carried out to determine the effect of E2 induced ROS on the transcription of cell cycle 
genes as shown in methods. Result obtained show an up-regulation in the transcription of 
CyclinB1, PCNA, CDC25C and PRC1 (Fig.9, Panels I&IIA). However, when cells were 
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co-treated with either CAT or Eb, there was a significant inhibition of E2 induced 
transcription upregulation of the same genes (Fig.9, Panels I&IIB). 
 
Discussion 
The results of our study show that estrogen-induced reactive oxidants have the capacity 
to stimulate cell proliferation in MCF7 breast cancer cells through the oxidation of 
PTEN, and the post translational modification of its downstream target.  
 
In line with previous work done 23, we are able to show here that estrogen-induced 
reactive oxygen species (ROS) is capable of promoting DNA synthesis and cell 
proliferation, which can be inhibited by exposure of the same cells to either biological or 
chemical antioxidants, Catalase or Ebselen (See figs. 1, 2 and 3).  
 
In this study, we have been able to show for the first time in MCF7 cells that estrogen-
induced ROS oxidizes PTEN within 30 minutes of exposure. In addition, we reveal here-
in the ability of either Catalase or Ebselen to reverse the oxidizing effect of estrogen-
induced ROS. See figs.4 and 5. We also show here that estrogen-induced PTEN 
inactivation in MCF7 cells results in an increase in the phosphorylation of one of its 
downstream target kinases, Akt. This is in line with previous studies which showed an 
increase in Akt phosphorylation following PTEN inactivation by agents other than 
estrogen 13, 24, 25. Moreover, we have also been able show that the pre-exposure of MCF7 
cells to either Catalase or Ebselen significantly reverses the E2-induced effect. See fig.6. 
Also demonstrated in this study is a corresponding increase in both the expression and 
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phosphorylation of NRF1, which is a known Akt substrate that has been implicated in 
cell growth and proliferation 18-20. (See figure 7). 
 
Based on the work done by Cam et al. 18, which showed NRF1 could collaborate with 
E2F family members to regulate the expression of genes that are involved in cellular 
proliferation, we explored the possibility of phosphorylated (active) NRF1 binding to the 
promoter region of cell cycle genes. Evident in our study for the first time in MCF7 cells, 
is an increase in the binding of Akt phosphorylated NRF1 to the promoter region of the 
following cell cycle genes: CyclinB1; CDC25A; CDC2; PCNA and PRC1. It is also 
worthy of mention that this promoter binding was significantly inhibited by the pre-
exposure of MCF7 cells to either Catalase or manganese superoxide dismutase 
(MnSOD). See fig. 8.  We were further able to reveal a consequent increase, in the 
transcription of these gene, which was also inhibited by pre-exposure to Catalase and 
MnSOD (See fig. 9). 
 
In summary we have been able to show for the first time in MCF7 cells, that estrogen-
induced ROS inactivates PTEN with an ensuing increase in Akt phosphorylation. This 
Increase in Akt phosphorylation results in an increase in NRF1 expression and 
phosphorylation leading to the activation and binding of NRF1 to the promoter region of 
some cell cycle genes, namely CyclinB1, CDC25A, CDC2, PCNA and PRC1 leading to 
cell proliferation. We also show a corresponding increase in the transcription of these 
genes. Additionally, we show for the first time that that pre-exposure of MCF7 cells to 
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either biological or chemical antioxidants significantly inhibited the effect of estrogen-
induced ROS on PTEN and its downstream substrates (See fig. 10). 
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Figures and Legend 
 
Fig 1-MCF7 
  
 
Antioxidants inhibit E2 induced ROS in MCF7 cells. 1 x104cells/well were seeded in a 
96-well plate overnight and serum starved for 24 hrs. Post-starvation 100uL/well of 
HBSS containing 10uM DCFH-DA pre-diluted with Pluronic F-127 was added to each 
well and incubated at 37oC for 20mins.  DCFH-DA solution was then aspirated and 
replaced with 100ul of HBSS containing the desired treatments. Cells were further 
incubated for 5mins and fluorescence readings were taken using 485 nm and 535 nm as 
excitation and emission filters, at intervals of 5mins. A) MCF7 cells treated with E2.  B) 
MCF7 cells over expressing Catalase (CAT) or pre-treated with Ebselen were exposed to 
either E2 or DMSO. Assay was performed 3x and data is expressed as mean percentage 
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change from control +/- SE, (p 0.05).  (*) denotes significance when treatment is 
compared to DMSO control.  
 
Fig 2-MCF7 
 
 
Antioxidants inhibit DNA synthesis in MCF7 cells. 2.5 x 103 cells/well were seeded in 
a 96-well plate overnight and exposed to chemical or biological antioxidants as described 
in methods. After exposure to antioxidants, cells were then stimulated with E2 for 22 hrs 
and pulsed labeled with BrdU for 2 hrs. BrdU assay was then carried out as 
recommended by manufacturer. Colorimetric changes were acquired at 370 nm with a 
Tecan Genios microplate reader at 5 mins interval. A) MCF7 cells treated with either E2 
or DMSO B) MCF7 cells over expressing Catalase (CAT) or pre-treated with Ebselen 
were treated with either E2 or DMSO. Assay was performed 3x and data is expressed as 
mean percentage change from control +/- SE, (p 0.05). (*) denotes significance when 
treatment is compared to DMSO control. 
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Fig 3-MCF7 
 
Antioxidants inhibit E2-induced anchorage independent growth in MCF7 cells. 
Cells were incubated on soft agar with or without antioxidants exposure for 21 days and 
colonies ≥60 microns in diameter were enumerated. A) Anchorage independent growth of 
MCF7 cells exposed to either DMSO or E2 B) MCF7 cells pretreated with chemical 
antioxidant.  Assay performed 3x and data is expressed as mean percentage change from 
control. 
 
 
 
 
 
 
 135 
Fig 4-MCF7 
 
 
 
Hydrogen Peroxide (H2O2) oxidizes PTEN in a dose dependent manner in MCF7 
cells. MCF7 cells were seeded and stimulated with different doses of H2O2 for 30min and 
then harvested. Cellular protein extracts were then alkylated with NEM and subjected to 
non-reducing SDS-PAGE followed by immunoblot analysis with antibodies to PTEN. 
Assay was performed 3x and data is expressed as mean percentage change from control. 
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Fig 5-MCF7 
 
 
Antioxidants inhibit the E2-induced PTEN oxidation in MCF7 cells. Cells were pre-
treated with Ebselen for 3hrs and stimulated with either DMSO or E2 for 30mins. 
Cellular protein extracts were then alkylated with NEM and subjected to nonreducing 
SDS-PAGE followed by immunoblot analysis with antibodies to PTEN.  A) MCF7 cells 
treated with either E2 or DMSO.  B) MCF7 cells over-expressing Catalase (CAT) or 
Empty Vector (EV) treated with DMSO or E2. C)  MCF7 cells pre-treated with Ebselen 
were treated with either DMSO or E2. Assay was performed 3x and data is expressed as 
mean percentage change from control +/- SE, (p 0.05). (*) denotes significance when 
treatment is compared to DMSO control while (**) denotes significance when treatment 
is compared EV control. 
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Fig 6-MCF7 
 
 
E2-induced PTEN oxidation activates Akt phosphorylation in MCF7 cells. Akt and 
phospho-Akt levels were determined post PTEN oxidation by immunoblotting using 
MCF7 cells pre-exposed with either biological (CAT) or chemical (Ebselen) antioxidants 
and then treated with E2 for 30min to induce PTEN oxidation. A) MCF7 cells treated 
with either E2 or DMSO B) MCF7 cells over-expressing Catalase (CAT) or Empty 
Vector (EV) treated with DMSO or E2. C)  MCF7 cells pre-treated with Ebselen were 
treated with either DMSO or E2. Assay was performed 3x and data is expressed as mean 
percentage change from control +/- SE, (p 0.05). (*) denotes significance when treatment 
is compared to DMSO control while (**) denotes significance when treatment is 
compared EV control. 
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Fig7-MCF7. 
 
 
 
E2 induces NRF1 expression and phosphorylation in MCF7 cells. 1.0 x104 
cells/chamber were treated for 45mins with E2.  Cells were then fixed with ice cold 
methanol for 15mins, and permeabilized with 0.5% Triton X-100 for 30mins after which 
they were blocked with 1% normal goat serum for 1hr and then probed simultaneously 
with antibodies for NRF1 (red) phosphoserine (blue).The merged  phosphorylated NRF1 
is in pink. 
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Fig 8-MCF7 
 
 
E2-induced ROS mediates NFR-1 binding to the promoter region of cell cycle genes. 
MCF7 cells were seeded, serum starved for 24 hrs and either infected with Adenovirus 
over- expressing MnSOD (SOD) or Catalase (CAT) at m.o.i of 200pfu as shown in the 
methods section. Cells were then exposed to either DMSO or E2 for 16hrs and harvested 
for ChIP assay as described in methods. PCR were run on ABI Biosystem 7300 
thermocycler with the following cycle conditions: 95 ºC, 10 min; 40 cycles of (95 ºC, 15 
sec; 60 ºC, 60 sec). PANEL I: PCR were run with primers for PRC1 and CDC2. A) 
MCF7 cells were treated with either E2 or DMSO B) MCF7cells over expressing CAT or 
SOD were treated with either DMSO or E2. Assay was performed 3x and data is 
expressed as mean percentage change from control. PANELII: PCR were run with 
primers for PCNA, CyclinB1 and CDC25C. A) MCF7 cells were treated with either E2 
or DMSO B) MCF7 cells over expressing CAT or SOD were treated with either DMSO 
 140 
or E2. Assays was performed 3x and data is expressed as mean percentage change from 
control. 
 
Fig 9-MCF7 
 
 
E2-induced ROS mediates transcription of cell cycle genes. MCF7 cells were seeded, 
serum starved for 24 hrs and either infected with Adenovirus over- expressing MnSOD 
(SOD) or Catalase (CAT) at m.o.i of 200pfu as shown in the methods section. Cells were 
then exposed to either DMSO or E2 for 24hrs and harvested for RT-PCR as described in 
methods. RT- PCR were run on ABI Biosystem 7300 thermocycler with the following 
cycle conditions: initial initiation Step set at 48oC for 30mins; and 95 oC  for 10min (1 
cycle) and the PCR step at 95oC for 15sec and 60sec for 1min (40 cycle). PANEL I: RT-
PCR were run with primers for CyclinB1. A) MCF7 cells were treated with either E2 or 
DMSO B) MCF7cells over expressing CAT or SOD were treated with either DMSO or 
E2. Assay was performed 3x and data is expressed as mean percentage change from 
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control. PANELII: RT-PCR was run with primers for PCNA, PRC1 and CDC25C. A) 
MCF7 cells were treated with either E2 or DMSO B) MCF7cells over expressing CAT or 
SOD were treated with either DMSO or E2. Assays was performed 3x and data is 
expressed as mean percentage change from control. 
 
Fig 10-MCF7 
 
 
 
A schematic showing our hypothesized pathway. Estrogen-induced ROS inactivates 
PTEN with an ensuing increase in Akt phosphorylation. This Increase in Akt 
phosphorylation results in an increase in NRF1 expression and phosphorylation leading 
to the activation and binding of NRF1 to the promoter region of some cell cycle genes. 
                 
V    CONCLUSION 
The goal of this dissertation was to investigate and hopefully reveal the role of ROS in 
the conversion of tamoxifen sensitive breast tumors to a tamoxifen-resistant phenotype. 
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Our research was based on the working hypothesis that excess ROS oxidizes protein 
tyrosine phosphatases (PTPs), thereby changing the phosphorylation state and altering the 
functions of certain key signaling proteins such as p27 (a Cyclin dependent kinase 
inhibitor) and nuclear respiratory factor 1(NRF-1) (a transcription factor).We further 
postulated that if ROS/redox signaling has a role in the development of tamoxifen 
resistance, then we may be able to restore sensitivity to tamoxifen by pre-exposing 
resistant breast cancer cells to antioxidants.  
  
In the course of our research, using tamoxifen resistant LCC2 breast cancer cells, we 
found tamoxifen to be highly pro-oxidant, based on its ability to induce ROS formation 
when it is used to stimulate LCC2 cells. We further discovered that tamoxifen acts as an 
ROS scavenger (antioxidant) in the presence of estrogen. Upon further investigation we 
found that stimulating LCC2 cells with tamoxifen resulted in a reduction in the 
expression of p27 protein and an increase in its phosphorylation on threoning 157 and 
187 respectively which correlated with an increase in cell proliferation. Interestingly, we 
were able to reverse these findings using biological (MnSOD and Catalase) and chemical 
(Ebselen) antioxidants. Meaning that LCC2cells which were pre-exposed to antioxidants 
showed a significant increase in p27 expression and a reduction in the phosphorylation of 
p27 implying a possible growth inhibitory effect.  
 
Our findings then raised a question about what aspect of p27 was really affected in the 
development of tamoxifen resistance. Was it a decrease in p27 expression or just the 
inability of the protein to carry out its growth inhibitory function? So we compared the 
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level of p27 in tamoxifen sensitive MCF7 breast cancer cells to that in tamoxifen resistant 
breast cancer cells and found that the level of p27 in LCC2 cells was significantly less 
than in MCF7 demonstrating that if tamoxifen resistance is as a result of a reduction in 
p27 expression, then our finding that pre-exposure to anti-oxidants t increases p27 
expression was a significant one. We then conducted a p27 stability assay comparing 
cells pre- exposed to anti-oxidant to those which were not. Again we found that those 
cells pre-exposed to anti-oxidants showed more p27 stability compared to those which 
were not. We also conducted a functional assay to determine the effect of our findings on 
the function of p27, again we found that cells which were pre-exposed to anti-oxidants 
were more functional because they exhibited more binding capacity of p27 to CyclinE 
and Cdk2 compared to cells which were not exposed to anti-oxidants. As mentioned 
previously in this dissertation, the growth inhibitory effect of p27 is based on its ability to 
bind to the CylinE-Cdk2 complex.  
 
Putting all our findings together we may therefore infer that, the development of 
tamoxifen resistance is due to the ability of tamoxifen to produce a sustained increase in 
ROS which results in a pro-oxidative environment. In a pro-oxidative environment the 
expression and stability of p27 is diminished resulting in loss of its inhibitory function 
because there is not enough p27 to bind and inhibit the growth promoting CyclinE-CDK2 
complex. Therefore our findings that anti-oxidants increased p27 expression, stability and 
binding are very significant. 
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To determine the mechanism of tamoxifen resistance, we used Tamoxifen sensitive 
MCF7 cells to determine the effect of ROS on the loss of tamoxifen sensitivity and 
demonstrated that in a pro-oxidant environment, the sustained increase in ROS level 
leads to the oxidation and inhibition of the phosphatase PTEN with a consequent increase 
in the phosphorylation of Akt. An increase in Akt phosphorylation then results in the 
phosphorylation and activation of NRF-1. We then demonstrated that activated NRF-1 
then binds to the promoter region of the following cell cycle genes: PCNA, cyclinB1, 
CDC25A and PRC1 leading to their transcription and culminating in a sustained cell 
proliferation. This finding could also be used to explain what happens in the case of p27 
because Akt has been shown to phosphorylate p27 on T157 resulting in the cytoplasmic 
sequestration of p27 and loss of its inhibitory function. 
 
In a nutshell, we have been able to experimentally demonstrate that ROS/redox signaling 
contributes to the evolution of breast cancer from a tamoxifen sensitive to a tamoxifen 
resistant phenotype. The Findings of this study will elucidate the roles of the cellular 
redox state, redox signaling pathways, PTPs and p27 in anti-estrogen resistance, and may 
lead to new therapeutic strategies to delay or even prevent this important clinical 
problem. This is a new line of research that may lay the groundwork for clinical trials of  
anti-estrogens plus antioxidant-based drugs for the prevention and treatment of estrogen-
dependent breast 
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Directions for future research 
As mentioned in the conclusion part of this dissertation, using MCF 7 cells we could also 
demonstrate the effect of Akt phosphorylation on T157 and subsequently p27 function. 
We have conducted preliminary studies in our lab and the results are encouraging. 
 
Since our current research was done in vitro, another area for further research would be a 
test of our hypothesis in vivo. Xenografted tumors in nude mice will be used to determine 
if ROS inhibitors or glutathione or thioredoxin modifiers can cooperate with anti-
estrogens to inhibit the proliferation of anti-estrogen-resistant breast cancer cells. 
Findings of this study will reveal the roles of the cellular redox state, redox signaling 
pathways and p27/NRF-1 in anti-estrogen resistance, and may lead to new therapeutic 
strategies to delay or even to prevent this important clinical problem. This is a new line of 
research that may lay the groundwork for clinical trials of anti-estrogens plus antioxidant-
based drugs for the prevention and treatment of estrogen-dependent breast cancer. 
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